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associated with advanced tumor stage 
and predicted poorer DSS. 
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ABSTRACT
Although pharyngeal squamous cell carcinoma (PSCC) is a rather rare disease its incidence
has been increasing over past 3 decades now accounting for 130 000 new cases and 80 000
cancer deaths worldwide. The prognosis is one of the poorest of all the head and neck
squamous cell carcinomas (HNSCC) and it has not improved to any significant extent
despite the availability of multimodal therapies. The main risk factors for PSCC are the use
of tobacco and alcohol. Recently the human papilloma virus (HPV) has been shown to be
involved in evolution and prognosis of oropharyngeal squamous cell carcinoma (SCC). No
other distinct biomarkers for PSCC patient survival have been established thus far.
Epithelial-mesenchymal transition (EMT) is a complex cellular process which is not only
crucial for embryogenesis but it is also activated during tumor progression, enabling tumor
cells to become invasive and to metastasize. Several transcription factors, like snai1, twist
sip1,  slug  and  zeb1,  are  fundamental  in  regulating  EMT.  The  role  of  EMT-related
transcription factors (EMT-RTFs) has not yet been established in PSCC.
In the present study, the immunohistochemical expressions of transcription factors snai1,
twist, sip1, slug and zeb1 were analyzed in tumor cell, stromal and endothelial cell nuclei as
well as in cytoplasm of PSCC samples in an effort to evaluate the association of their
expressions to clinicopathological variables and patient prognosis. Snai1 expression in
endothelial cell nuclei predicted a reduced disease specific survival (DSS). Snai1 expression
in endothelial and stromal cell nuclei also associated with hypopharyngeal tumors,
increased  T-stage  (T3-4)  and  poor  general  condition  of  the  patient.  Those  tumors  which
displayed intense stromal staining of twist relapsed more frequently.  In contrast, those
tumors with negative immunostaining of twist and snai1 in stromal cell nuclei were smaller
(T1-2), less advanced (Stage I-II) and located more often in the oropharynx. Those patients
also  had  a  better  5-year  DSS  and  overall  survival  (OS).  Tumors  with  positive  epithelial
nucleal sip1 immunostaining were more advanced (Stage III-IV) and had more lymph node
metastases.  Sip1 immunoreactivity significantly correlated with DSS and OS. Epithelial
sip1 was an independent prognostic factor in Cox proportional hazards model together
with Karnofsky performance status score and T-stage. In the same multivariate analysis, co-
expression of snai1, twist and sip1 in tumor epithelial cell nuclei predicted even poorer
prognosis than sip1 expression alone.
     In conclusion, sip1 seems to be a potential new prognostic factor in PSCC, and might be
applicable for clinical use to indicate those patients with more ominous tumor behavior
requiring more aggressive therapy and closer follow-up.
National Library of Medicine Classification: WV 190, QZ 365, QS 532.5.C7, QS 532.5.E7, QU 475, QW 504.5
Medical Subject Headings: Carcinoma, Squamous Cell/pathology; Disease Progression; Endothelium,
Vascular; Epithelial-Mesenchymal Transition; Head and Neck Neoplasms; Immunohistochemistry;
Pharyngeal Neoplasms/pathology; Prognosis; Stromal Cells/pathology; Transcription Factors;
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TIIVISTELMÄ:
Nielun levyepiteelikarsinooma on varsin harvinainen sairaus, jonka esiintyvyys on
kuitenkin noussut viimeisen 30 vuoden aikana. Uusia tapauksia ilmaantuu vuosittain
130 000 aiheuttaen 80 000 syöpäkuolemaa maailmanlaajuisesti. Taudin ennuste on huonoin
kaikista pään ja kaulan alueen syövistä eikä ole parantunut viime aikoina huolimatta
uusista hoitokeinoista. Tärkeimmät riskitekijät ovat tupakka ja alkoholi, joskin
papilloomaviruksen on viime aikoina osoitettu vaikuttavan suunielun
levyepiteelikarsinooman ilmiasuun ja ennusteeseen. Yksiselitteisiä ennusteen arvioinnissa
käytettäviä biomerkkiaineita ei toistaiseksi ole käytössä nielusyövässä.
     Epiteliaali-mesenkymaalinen transitio (EMT) on monimuotoinen prosessi, joka on
välttämätön sikiökehitykselle mutta sen on todettu käynnistyvän myös syöpäsoluissa. Sen
myötä kasvainsolut saavat kasvua ja metastasointia edistäviä ominaisuuksia. Snai1, twist,
sip1, slug ja zeb1 ovat EMT:n säätelytekijöitä, joiden merkitystä nielusyövässä ei ole
aiemmin selvitetty.
     Tämän väitöskirjatyön tarkoitus oli selvittää yllä mainittujen säätelytekijöiden
ilmentymistä kasvainsolujen, tukikudosten solujen sekä verisuonten endoteelisolujen
tumissa sekä sytoplasmassa immunohistokemiallisin menetelmin ja arvioida ilmentymisen
yhteyttä potilaan ennusteeseen ja kliinis-patologisiin muuttujiin. Snai1:n ilmentyminen
kasvaimen endoteelisoluissa oli yhteydessä huonoon ennusteeseen, suureen
kasvainkokoon (T3-4), kasvaimen sijaintiin alanielun alueella sekä potilaan alentuneeseen
yleistilaan. Twist-positiivisuus kasvaimen tukikudoksessa liittyi suurempaan taudin
uusimisriskiin. Kasvaimet, joiden tukikudossolut eivät ilmentäneet snai1:tä eivätkä twist:ä
olivat pienempiä (T1-2) ja sijaitsivat useammin suunielussa. Näiden potilaiden ennuste oli
merkitsevästi parempi. Pitkälle edenneiden (Stage III-IV), kaulalle etäpesäkkeitä jo
tehneiden kasvainten tumissa todettiin usein sip1-proteiinia. Tämä ilmentyminen korreloi
merkitsevästi potilaiden kuolleisuuteen ja oli myös itsenäinen ennustetekijä monimuuttuja-
analyysissä yhdessä T-luokan ja potilaan yleistilan kanssa. Kun sekä snai1, twist että sip1
ilmentyivät yhtä aikaa kasvainsolujen tumissa, potilaan ennuste oli erittäin huono; tämä
löydös oli niin ikään itsenäinen ennustetekijä monimuuttuja-analyysissä yhdessä T-luokan
ja potilaan yleistilan kanssa.
     Väitöskirjatyön perusteella sip1-proteiinia voidaan pitää mahdollisena nielusyövän
ennustemerkkiaineena, joka voisi soveltua kliiniseenkin käyttöön osoittamaan
agressivisesti käyttäytyvät kasvaimet.
Luokitus: WV 190, QZ 365, QS 532.5.C7, QS 532.5.E7, QU 475, QW 504.5
Yleinen Suomalainen asiasanasto: : kasvaimet; okasolusyöpä; ennusteet; immunohistokemia
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1 Introduction
Head and neck cancer (HNC) comprises a group of malignant tumors originating in several
anatomical areas but over 90% of them are squamous cell carcinomas (SCC).(1) Pharyngeal
squamous cell carcinoma (PSCC) includes nasopharyngeal, oropharyngeal and
hypopharyngeal subsites. Nasopharyngeal carcinoma differs extensively both histologically
and  biologically  from  the  other  pharyngeal  carcinomas  and  therefore  it  will  not  be
discussed  in  this  thesis.  The  incidence  of  PSCC  has  been  increasing  over  the  past  three
decades and now it accounts for 130 000 new cases and 80 000 cancer deaths
worldwide.(2,3) The prognosis is one of the poorest among all head and neck squamous cell
carcinomas (HNSCC) and has not improved despite the advances in multimodal therapies.
PSCC is  typically  diagnosed at  an advanced stage.  The delay in  diagnosis,  appearance  of
second primaries and locoregional recurrences together with heterogenic, unpredictable
tumor behavior all contribute to the poor prognosis.(4,5) The prognosis and recommended
treatment modalities are determined mainly by the tumor-node-metastasis (TNM) status.(6)
The  main  risk  factors  for  PSCC  are  the  use  of  tobacco  and  alcohol.  Recently  human
papilloma virus (HPV) has been discovered to be involved in the appearance and prognosis
of oropharyngeal SCC.(7-10)
Carcinogenesis  is  a  multistep  process  characterized  by  the  gradual  accumulation  of
mutations in cancer cells. These transformed cells also modify their surrounding stromal
tissue, a connective tissue framework with fibroblasts, inflammatory cells, fat cells and
blood vessels creating a tumor growth supporting environment. Normal stromal fibroblasts
are capable of inhibiting tumor growth but during tumor progression, the
microenvironment shifts towards a growth-promoting nature and tumor associated
fibroblasts become promoters of tumor progression. (11,12)
     Epithelial-mesenchymal transition (EMT) is a complex cellular process crucial in
embryogenesis but which is also activated during tumor progression and wound
healing.(13,14) In the course of EMT, epithelial cells lose their organized arrangement and
cohesion and acquire motile as well as invasive characteristics, enabling them to invade and
metastasize. EMT is characterized by downregulation of certain epithelial adhesion
moleclules such as E-cadherin along with the upregulation of mesenchymal genes like N-
cadherin, -smooth muscle actin and vimentin.(15) EMT is driven by extracellular
signalling suchas that provided by soluble growth factors derived from surrounding tumor
and stromal cells as well as environmental stimuli e.g. hypoxia.(16)
     The EMT-process is regulated by several transcription factors including snail
superfamily (snai1, snai2[l.slug] and snai3), twist with its family members as well as the zeb
superfamily  (zeb1  and  zeb2  [l.sip1]).  All  of  those  factors  induce  EMT  by  provoking  E-
cadherin downregulation via binding to its promoter region.(17-20) These EMT- related
transcription factors (EMT-RTFs) have also several other functions in tumorigenesis
including  blockade  of  the  cell-cycle  and  preventing  cells  from  undergoing  apoptosis,  as
well as regulating cell polarity and angiogenesis. (21-27) The overexpression of EMT-RTFs
has  been  associated  with  a  poor  outcome  in  many  human  cancers.  Snai1  expression  in
laryngeal SCC associated with local recurrence and stromal immunoreactivity of snai1
correlated with curtailed disease specific survival (DSS) in patients with colon
adenocarcinomas.(28,29) Similarly, slug overexpression has been related to aggressive
tumor behavior and poor survival in patients with oesophageal SCC.(30) High twist
expression associated with aggressive tumor properties and poor prognosis in oesophageal,
breast and cervical SCC.(31-33)  There is a report that sip1 was an independent prognostic
factor in oral SCC.(34) There is also evidence of co-expression of EMT-RTFs resulting in a
synergistic enhancement effect. The co-expression of twist and snai1 in hepatocellular
2carcinoma  and  small-cell  lung  cancer  predicted  worse  overall  survival  (OS)  than  either
positive transcription factor alone.(35,36) However, according to other reports, the
expression of EMT-RTFs does not seem to associate with tumor progression in several other
carcinomas.(37-39) This highlights the versatile and complex roles of EMT-RTFs in distinct
tumors.  No  studies  addressing  the  role  of  EMT-RTFs  in  PSCC  have  been  published
previously.
     In the present study, the immunohistochemical expressions of transcription factors snai1,
twist,  sip1, slug and zeb1 were analyzed in tumor cells as well as stromal and endothelial
cell nuclei and cytoplasm of PSCC samples in an attempt to evaluate the associations
between their expressions, clinicopathological variables as well as with patient prognosis.
32 Review of the Literature
2.1 PHARYNGEAL SQUAMOUS CELL CARCINOMA
2.1.1 Anatomy of the pharynx
Pharynx is anatomically divided into three regions: nasopharynx, oropharynx and
hypopharynx. Pharynx is a part of the upper aerodigestive track taking also part in voice
formation and immunological defence. This thesis focuses on oro- and hypopharynx, which
form a histopathologically and therapeutically distinct entity. Oropharynx is bounded
proximally by the posterior edge of the hard palate and distally by the valleculae and hyoid
bone. The posterior limit is defined by the muscular pharyngeal wall whereas the
circumvallate papillae and palatoglossal muscle mark the anterior border. The lateral walls
of the oropharynx are composed of the tonsillae and tonsillar fossae. (40) (Figure 1.) The
hypopharynx lies posterior to the larynx extending from superior border of epiglottis to the
inferior border of cricoid cartillage and further down to the superior oesophageal sphincter.
The posterior border is formed by pharyngeal inferior constrictor muscles and laterally,
forming lateral borders of pyriform sinuses are thyroid cartilage and thyrohyoid
membranes. The subsites are presented in table 1 and Figure 2.
Table 1.  Oro-and hypopharyngeal subsites. Modified from TNM classification of the malignant
tumors. 7th edition. Sobin et al. (2010)
Site
OROPHARYNX
 1. Anterior wall (glosso-epiglottic area)
    1.1 Base of tongue (posterior to the vallate papillae or posterior
    third)
    1.2 Vallecula
 2. Lateral wall
    2.1 Tonsil
    2.2 Tonsillar fossa and tonsillar (faucial) pillars
    2.3 Glossotonsillar sulci (tonsillar pillars)
 3. Posterior wall
 4. Superior wall
     4.1 Inferior surface of soft palate
         4.2 Uvula
HYPOPHARYNX
1. Pharyngo-oesophageal junction
2. Pyriform sinus
3. Posterior pharyngeal wall
4Figure 1. Anatomy of pharynx, lateral view. (Modified from www.greenfacts.org)
Figure 2. Oropharyngeal subsites, anterior view. (www.wehealny.org)
Nasopharynx
Oropharynx
Hypopharynx
5Cervical lymph nodes sites are divided into six regions. In PSCC, the lymph nodes in the
regions II-IV have the highest probability for metastases.(41)
Figure 3. Cervical lymph node regions, lateral view. (www.sciencedirect.com)
2.1.2 Risk factors and epidemiology
The consumption of tobacco and alcohol are the best-known risk factors for pharyngeal
carcinoma. Acetaldehyde, the major metabolite of ethanol, has been proved to be
carcinogenic not only in animals but also in humans.(42) the levels of acetaldehyde in saliva
are higher among smokers than non-smokers and smoking combined with alcohol
consumption may increase the saliva acetaldehyde levels by as much as 7-fold.(43)
Environmental tobacco smoke has also been reported to increase the risk for HNSCC.(44)
Betel nut chewing is an important risk factor not only for oral but also pharyngeal SCC,
especially in Asia.(45) Human papilloma virus (HPV), mainly type 16 and to a lesser extent
18, is a newly identified risk factor especially for carcinomas of the tonsils and the base of
the tongue. According to the molecular analyses, 35-73% of oropharyngeal carcinomas are
HPV  positive  and  this  percentage  seems  to  be  rising.(7-10)  HPV16  genomic  DNA  was
detected  in  up  to  72%  of  the  oropharyngeal  cancers.(1,7)  A  diet  poor  in  fruit  and  low  in
vitamine increases the risk for PSCC.(46) In contrast, recreational physical activity seems to
protect from HNC, especially among smokers and drinkers.(47)
HNSCC,  which  can  be  located  in  several  anatomic  areas,  is  the  sixth  most  prevalent
malignancy in the world with approximately 900 000 cases diagnosed annually
worldwide.(48) Of all HNSCCs, pharyngeal carcinoma constitutes less than one sixth
accounting for 130 000 new cases and over 80 000 deaths yearly worldwide.(3,49,50)
Incidence rates of oral and pharyngeal cancer among men are 2-4 higher than those among
women and the vast majority of patients are over 45 years old at the time of diagnosis.(10)
6However, there are increasing rates of cancer of the tongue being diagnosed in young men
and women. The former disparity between sexes has decreased progressively during the
recent  decades  in  several  HNCs.(4,10)  The  incidence  of  oropharyngeal  carcinoma  is
increasing  in  spite  of  a  decreasing  prevalence  of  smoking.(2)  In  Finland  the  overall  age-
adjusted incidence of pharyngeal carcinoma was 0.89 per 100 000 inhabitants between years
1986 and 1996; 1.28 in men and 0.60 in women.(51) In the last 20 years, the incidence of
oropharyngeal carcinoma increased from 0.66 to 1.36/100 000 person-years and the relative
frequency of p16 positive PSCC has increased from 22% to 41% during the same time
period.(2)
2.1.3 Histopathology and grading
Over 90% of the pharyngeal carcinomas are squamous cell carcinomas (SCC) originating
from the mucosal epithelium. The World Health Organization (WHO) histological grading
of SCC has been descibed by Shanmugaratnam.(52) Tumors are classified into three groups
according to their cellular structure and differentiation, nuclear polymorphism and
frequency of mitoses: well differentiated (Gr1), moderately differentiated (Gr2) and poorly
differentiated (Gr3). The majority, 60% of oropharyngeal carcinomas are moderately
differentiated, 20% are well differentiated and 20% are poorly differentiated.(53)
Histological variants are rare and include verrucous, basaloid, spindle cell and
adenosquamous carcinomas. (1) The other more rare pharyngeal malignancies include
sarcomas, lymphomas, adenocarcinomas, mucoepidermoid carcinomas and melanomas.
(54,55)
2.1.4 Presentation and diagnosis
The typical symptoms of PSCC are sore throat, tongue pain, poorly fitting dentures, otalgia,
dysphagia, odynophagia, cough, mouth bleeding, voice changes, airway symptoms and
weight loss. In the physical examination a pharyngeal mass or ulceration is often apparent.
(1) Pain is usually a late symptom indicative of advanced disease and it is often transposed
outside the pharyngeal area via vagal and glossopharyngeal nerve irritation.(1,56) The first
manifestation of PSCC is unfortunately often a neck tumor as a sign of a lymph nodal
metastasis. PSCC is often diagnosed at an advanced stage with the involved cervical lymph
nodes.(57) The incidence of distant metastases at the time of diagnosis is approximately
10%  the  most  common  site  being  lung,  followed  by  mediastinal  lymph  nodes,  liver  and
bone.(1,58)
     The  diagnosis  of  pharyngeal  carcinoma  is  based  on  thorough  physical  examination  of
the upper aerodigestive track and biopsy of the primary tumor. The role of computer
tomography (CT) and magnetic resonance imaging (MRI) in evaluating the local extent,
regional spread and distant metastases has been universally accepted. They both show
similar sensitivities and specificities in detecting cervical lymph node metastases.(59) MRI
is  the  most  effective  means  for  a  local  assessment  of  oropharyngeal  cancer  but  CT  is  less
sensitive to movement artifacts and is quicker to perform.(60) MRI is of better diagnostic
value for mandibular invasion but both imaging techniques experience difficulties in
precisely assessing cartilaginous extensions. (61),(62,63)  Cervicothoracic CT is thought to
be a part of the initial staging in oro-and hypopharyngeal cancer.(60) Routine screening of
other possible metastatic sites is not warranted in PSCC.(64,65) Neck ultrasound with fine
needle  aspiration  biopsy   is  an  established  method  in  confirming  cervical  lymph  node
metastases.(59) In some patients, panendoscopic assessment under general anesthesia
including also  the esophagus and tracheobronchial tree is recommended as a way to assess
the  precise  tumor  status.  This  technique  is  also  valuable  in  cases  of  unknown  primary
tumor and also for excluding possible second primary tumors.(56) The incidence of second
primaries has been around nine per cent in retrospective studies and in systematic
panendoscopic explorations.(58,66,67) Positron emission tomography (PET) scanning
7combined  with  CT  is  a  method  which  is  being  increasingly  used  in  PSCC  diagnostics.  It
seems to be outstandingly effective in demonstrating primary tumors in cases of metastatic
adenopathy and also in evaluating the response to chemoradiotherapy.(68,69) Narrowband
imaging endoscopy uses a series of emission wavebands selected according to hemoglobin
absorption spectra. This improves visualization of microvasculature and tissue micro-
architecture giving assistance in the early diagnosis of cancerous and pre-cancerous
mucosal lesions.(70)
2.1.5 Staging
TNM classification is a worldwide and universally accepted practise for reporting the
extent of the malignant disease. The treatment modalities are determined mainly according
to  the  classification  and  it  is  also  a  major  tool  in  predicting  the  outcome  for  the  cancer
patient. TNM classification was defined by the International Union Against Cancer (UICC)
over 50 years ago and is still widely applicable today as regularly updated and practical
clinical  tool.(6)  In  this  classification,  T  characterizes  the  spread  of  the  primary  tumor,  N
describes the extent of regional lymph node metastases and M is the presence of distant
metastases.(71) The clinical (cTNM) staging is based on clinical examination, biopsy and
imaging prior to treatment.  The pathological staging (pTNM) allows detecting occult
metastases.  Additionally  extracapsular  spreading  of  the  primary  tumor  can  be
observed.(48) The numbering after the letters indicates the extent of the disease. In
uncertain cases, lower class must be selected. The TNM classification and stage grouping in
oro-and hypopharyngeal carcinomas are presented in table 2.
Table 2. TNM class and stage for PSCC, Modified from TNM classification of malignant tumors.
7th edition. Sobin et al. (2010)
T- Primary tumor
OROPHARYNX
T1  2 cm in the greatest dimension
T2  >2 cm to 4cm in the greatest dimension
T3  > 4 cm in the greatest dimension
T4a Invades to larynx, deep/ extrinsic
muscles of tongue, medial pterygoid, hard palate or mandible
T4b Invades to lateral pterygoid muscle,
pterygoid plates, lateral nasopharynx, skull base or encases the
carotid artery
 HYPOPHARYNX
     T1 Limited to one subsite and  2 cm or in the greatest dimension
     T2 Invades more than one subsite or an adjacent site, or measures > 2 to 4cm
     T3 > 4 cm in the greatest dimension, or with fixation of hemilarynx
     T4a Invades to thyroid/cricoid cartilage, hyoid bone, thyroid gland or oesophagus
     T4b Invades prevertebral fascia, encases carotid artery, or invades mediastinal structures
8    N – Regional lymph nodes (Oropharynx and Hypopharynx)
    NX  Regional lymph nodes cannot be assessed
    N0  No regional lymph node metastasis
    N1  Single ipsilateral lymph node metastasis 3 cm
    N2  N2a Single ipsilateral lymph node metastasis > 3 cm to 6 cm
 N2b Metastasis in multiple ipsilateral lymph nodes,  6 cm
 N2c Metastasis in bilateral or contralateral lymph nodes,  6 cm
    N3  Metastasis in a lymph node > 6 cm
    Note: Midline nodes are considered as ipsilateral nodes.
    M- Distant metastasis
    Mx Cannot be assessed
    M0 No distant metastasis
    M1 Distant metastasis exists
    Stage Grouping (Oropharynx and Hypopharynx)
    Stage 0 Tis N0 M0
    Stage I T1 N0 M0
    Stage II T2 N0 M0
    Stage III T1 N1 M0
T2 N1 M0
T3 N0-N1 M0
    Stage IVA T4 N0-N1 M0
anyT N2 M0
    Stage IVB anyT N3 M0
    Stage IVC anyT anyN M1
2.1.6 Treatment
The main treatment modalities used in PSCC are surgery, radiotherapy and chemotherapy
and their combinations. There are not globally, not even nationally standardized treatment
protocols.  Instead the therapy chosen depends upon each center’s modus operandi and
tradition as well as the patient’s characteristics. Surgery is traditionally a standard
treatment for HNSCC but is frequently limited by the anatomical extent of the tumor.(1)
Surgical  management  provides  a  pathological  staging  of  the  primary  tumor  and  regional
lymph  nodes  for  guiding  adjuvant  treatment  decisions.  The  use  of  open  surgery  as  the
initial treatment of oro- and hypopharyngeal cancer has been declining over the past three
decades.(72,73) Transoral robotic surgery (TORS) has been proposed to hold great potential
for  minimally  invasive  extirpation  of  oropharyngeal  cancer.  In  selected  cases  it  enables
radical resection and reconstruction avoiding the side-effects of adjuvant therapy.(74-77) In
addition, transoral laser microsurgery offers a minimally invasive endoscopic surgical
approach for certain oropharyngeal tumors.(78) However, open surgery has an important
9role as a salvage procedure after radiotherapy in cases where there are residual tumors or
local or locoregional recurrence. In PSCC this often includes pharynolaryngectomy. Free
microsurgical flaps have considerably improved the functional and cosmetic results of
surgery.(79)  When  surgery  is  a  primary  treatment,  neck  dissection  is  carried  out  in  most
cases as a part of surgical management.(40) The classic radical neck dissection has made
way for the less morbidizing selective neck dissection, the operated nodal regions
depending on the subsite and extent of the primary tumor.(48) In early N0 oropharyngeal
SCCs, sentinel node biopsy seems to represent a promising alternative to elective neck
dissection.(80) Postoperative radiotherapy is warranted in those cases with close or positive
excision margins, nodal metastases, bone erosions as well as perivascular or perineural
spread of the tumor are seen.(8,56)
     In spite of advances in the surgical field, radiotherapy is still  the treatment of choice in
many oropharyngeal and nearly all hypopharyngeal carcinomas. Chemoradiotherapy with
cisplatin, fluorouracil or the taxanes is the standard treatment for patients with advanced
disease. Chemoradiotherapy, and surgery followed by radiotherapy has been reported to
achieve equivalent results in locoregional control and survival in hypopharyngeal SCC.(81)
The advantages of radiotherapy lie in organ preservation, as surgery in the pharyngeal area
nearly always leads to major functional and cosmetic defects. Another advantage associated
with radiotherapy is the simultaneous treatment of subclinical nodal spread.(57) Intensity
modulated radiotherapy (IMRT) and altered fractionating schedules have diminished the
side effects to salivary glands, pharyngeal muscles and bones and also improved the loco-
regional control.(1,56,72,82) HPV-virus positive oropharyngeal tumors have been shown to
be highly radiation sensitive, for this reason radiation therapy could be the treatment of
choice in those cases.(9)
     The epidermal growth factor receptor (EGFR) has been identified as a therapeutic target
for several malignomas, including HNSCC. EGFR can be targeted either by antibodies or by
EGFR tyrosine  kinase  inhibitors.(8)  Treatment  with  Cetuximab,  a  humanized mouse anti-
EGFR monoclonal antiboby has improved locoregional control and overall survival in
combination with radiotherapy in locally advanced HNSCCs.(83,84)
2.1.7 Follow-up and survival
The  aims  of  follow-up  in  PSCC  are  evaluation  of  therapeutic  efficacy,  management  of
impairments, detection of loco-regional relapses and second primary tumors as well as the
provision of psychosocial support.(85) The early follow-up period starts one month after
treatment and ends two years later. Morbidity and mortality during this period result either
from locoregional recurrence or the complications of therapy.(58) The majority, 70% of new
tumor manifestations have been reported to take place during that period.(85) The late
follow-up period starts at the beginning of the third year and continues case-dependently,
usually at least 5 years from treatment. Morbidity and mortality during that period are
typically attributable to delayed regional or distant metastases, second primary tumors or
other medical conditions.(58)
     HNSCC is the sixth leading couse of cancer deaths worldwide and the 5-year survival is
still as low as 40 to 50%.(8) In fact, of all HNSCCs, pharyngeal carcinoma has the poorest
prognosis. The mean age-adjusted mortality rate of PSCC in Finland is 1.0 and the mortality
rate has increased by more than 3 %-units during the last 10 years.  The 5-year survival in
Finland  is  40%  for  men  and  49%  for  women.(Finnish  cancer  registry,
www.cancer.fi/syoparekisteri/) Survival depends on tumor stage and site. Hypopharyngeal
carcinoma has the poorest prognosis of the pharyngeal subsites. In a Finnish survey, the
median disease-free survival was 27.6 months for patients with oropharyngeal carcinoma
and 17.7 months for those with hypopharyngeal carcinoma.(51) There are several reasons
for  PSCC  treatment  failures  i.e.  tumor  recurrences  at  the  primary  site,  delayed  regional
metastases or delayed distant metastases. According to a Danish study, a recurrent primary
tumor is two times more common than a locoregional recurrence in oropharyngeal
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carcinoma.(57) Hypopharyngeal tumors carry risks as high as 24% for delayed regional
lymph nodal metastases and a 17% incidence of delayed distant metastases.(58,86) In a
retrospective study conducted in 2550 patients, the incidence of second primaries in
hypopharyngeal SCC was 8.9%.(58)
2.2 PROGNOSTIC FACTORS
2.2.1 Clinical prognostic factors
The  general  condition  of  the  patient  at  the  time  of  diagnosis,  as  defined  by  Karnofsky
performance  status  (KPS)  (table  3),  is  a  common  prognostic  marker  which  provides
consistent results in PSCC.(87,88) In a retrospective study of 3373 patients with HNSCC, the
most decisive variable for prognosis was the T category.(89) According to the same study,
other significant prognostic factors in multivariate analysis were alcohol consumption, KPS
score, primary site and N class.(89)  In  a study of  289 patients with oropharyngeal SCC, T
class also proved to be the most relevant prognostic factor together with the age of the
patient as well as their gender and haemoglobin level. The stage did not exert such a major
effect on prognosis, further highlighting the role of the primary tumor size over the
lymphonodal status.(57) In neither of those studies did the histological grading play any
significant role as a prognostic factor.(57,89) In oropharyngeal carcinoma, the subsite of the
tumor also had an influence on prognosis, i.e. it is best in tumors in the posterior wall and
worst  when  the  tumor  is  in  the  base  of  tongue.(90)  In  a  population-based  study  of
pharyngeal  cancer  incidence  and  survival  in  northern  Finland,  the  most  important  factor
affecting poor prognosis was Stage IV tumor.(51) Furthermore, HPV-positivity and non-
smoking status predicted a remarkably better prognosis in patients with oropharyngeal
SCC.(7) Smoking seems to have even greater prognostic value; HPV positive non-smokers
have significantly better DSS than their HPV positive smoking counterparts.(91)
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Table 3. Karnofsky performance status. Modified from Karnofsky 1948.(87)
Definition % Criteria
Able to carry on normal activity and to 100 Normal; no evidence of disease.
work. No special care is needed. 90 Able to carry on normal activity; minor signs of
symptoms of disease.
80 Normal activity with effort; some signs of symtoms
of disease.
Able to work and live at home, care for most
personal needs. A varying amount of
70 Cares for self. Unable to carry on normal activity or
to do active work.
assistance is needed. 60  Requires  occasional  assistance,  but  is  able  to  care
for most of needs.
50 Requires considerable assistance and frequent
medical care.
Unable to care for self. Requires equivalent
of institutional or hospital care.
40 Disabled; requires special care and assistance.
Disease may be progressing rapidly. 30 Severely disabled; hospitalization is indicated
although death is not imminent.
20 Very sick; hospitalization and active supportive
treatment is necessary.
10 Moribund; fatal processes progressing rapidly.
0 Dead
2.2.2 Molecular prognostic markers
There  are  several  biological  mediators  and  mechanisms  that  have  been  implicated  in
HNSCC progression.  However, at present only a few of those have been shown to possess
any  clinical  relevance.  The  most  common  genetic  changes  occurring  in  HNC  progression
are inactivation of tumor suppressor genes p16 and p53. The p16 gene inhibits cyclin-
dependent kinase (CDK), thus its inactivation leads to uncontrolled cell-cycle progression
as well as escape from senescence and apoptosis. In spite of its role as a tumor suppressor
gene, p16 overexpression also correlates higly with HPV positivity.(9,91)  Clinically, the p16
positive tumors display much of the same characteristics as the HPV positive tumors.(92)
Thus,  p16  has  continued  to  be  investigated  as  an  independent  tumor  marker  in  HNSCC.
HPV and p16 correlated with poorly differentiated histological grade as well as with nodal
metastases  in  a  study  of  HNSCC  tumors.(92)   Increased  expression  of  EGFR  has  recently
been associated with aggressive tumor behavior, resistance to chemotherapy and poor
prognosis in oropharyngeal cancer.(93) However, in another oropharyngeal SCC material
and  in  a  HNSCC  study  it  was  not  an  independent  prognostic  factor.(94,95)   The
Transforming growth factor 1 (TGF1)  genotype  has  been  associated  with  a  favorable
outcome in HNSCC patients, independently of p16 expression.(95)  Amplification of proto-
oncogen cyclin D1 is seen in about one third of the HNC cases and this is usually associated
with an invasive disease.(79)
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2.3 EPITHELIAL-MESENCHYMAL TRANSITION (EMT)
2.3.1 General considerations
Epithelial cells form layers of cells that are closely joined together by specialized membrane
structures e.g. tight junctions, adherens junctions, desmosomes and gap junctions. In
addition, epithelial cells display apical-basolateral polarization which is characterized by
the polarized organization of  the  actin  cytoskeleton and the  presence of  a  basal  lamina at
the basal surface. Mesenchymal cells, on the contrary, do not form organized layers or have
apico-basolateral polarization. Fiboblastic cells contact neighboring cells only focally and
are not associated with the basal lamina. Unlike the cuboidal form of the epithelial cells,
mesenchymal cells exhibit a spindle-shaped fibroblast-like morphology.(15) EMT is
considered as a process during which epithelial cells lose their epithelial phenotype and
acquire mesenchymal features.(13,96-98) These changes in cell connections and morphology
lead to looser cell-cell -contacts and the acquisition of cellular motility, both of which enable
invasion (fig. 4).
Figure 4. Epithelial and mesenchymal phenotypes and commonly used cell markers
characterized to each type. (Kalluri et al. 2009, reprinted by permission of publisher)
There are three types of EMT which become manifest under different circumstances.
Type 1  occurs  during implantation,  embryo formation and organ development  and it  is  a
self-contained process. Primary EMT events take place during the implantation of embyo
into the uterus, during gastrulation and during neural crest formation.(99,100) This primary
mesenchyme can be re-induced to form secondary epithelia by a mesenchymal-epithelial
transition (MET)  which is  a  reverse  process  and crucial  in  forming distinct  cell  types  as  a
part of organogenesis during secondary and tertiary EMT processes.(96,100) Type 2 is
associated with wound healing and tissue regeneration and it ceases once repair has been
achieved and inflammation is attenuated. In the setting of organ fibrosis, EMT can continue
to respond to ongoing inflammation and lead to organ destruction.(99,101) Type 3 occurs in
epithelial  cancer  cells  due  to  genetic  and  epigenetic  alterations  affecting  oncogenes  and
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tumor suppressor genes which make the cells especially responsive to heterotypic signals
originating from tumor microenvironment. Cells generated by type 3 EMT are typically
seen at the invasive front of the primary tumor and considered to be cells that may invade
and metastasize leading to systemic manifestations of cancer progression.(13,15,99,101)
2.3.2 Biomarkers for EMT
Presence of E-cadherin is one of the main feathures of the epithelial phenotype. E-cadherin
is the main constituent of adherens junctions but it promotes also the formation of
desmosomes.(13) Its expression is decreased during EMT. Moreover, the loss of E-cadherin
promotes EMT by inducing the expression of twist and zeb1.(102) There are other markers
for epithelial phenotype for example cytokeratin, mucin-1, desmoplakin, occludins,
claudin-1 and claudin-7.(15) In addition to the loss of epithelial markers, an increase in the
expression of mesenchymal markers such as N-cadherin, vimentin, fibronectin and smooth-
muscle  actin  is  also  a  characteristic  of  EMT  (fig.  4).(99,103)  The  cadherin  switch  from  E-
cadherin to N-cadherin has often been used to monitor the progress of EMT.(99,103) -
catenin is localized in the cell membranes in normal epithelial cells linking cadherins to the
intracellular cytoskeleton. During EMT, as a result of E-cadherin loss, -catenin relocalizes
to either cytoplasm or nucleus.(15) Matrix metalloproteases (MMP) are secreted proteases
that can digest the components of the extracellular matrix (ECM) and other junctional
proteins involved in cell-cell as well as in cell-ECM adhesion.(104) They have been
designated  also  as  mesenchymal  markers  which  are  frequently  overexpressed  in  tumor
cells.(105)
2.3.3 EMT signaling
EMT is triggered by the interplay of extracellular signals, including soluble growth factors,
components of the extracellular matrix as well  as by intracellular cues (Fig. 5).(97) During
development, EMT is induced by receptor tyrosine kinases (RTKs), which are activated by
several  soluble  growth  factor  signals,  such  as  TGF-,  fibroblast  growth  factor  (FGF),
insulin-like  growth  factor  (IGF),  platelet  derived  growth  factor  (PDGF)  and  epidermal
growth  factor  (EGF).(106,107)  In  most  cellular  models,  EMT  is  induced  by  the  interaction
between  overexpressed  RTKs  and  TGF- signaling.(108)  Growth  factors  are  produced
either  by  tumor  cells  or  by  the  surrounding  stromal  cells  and  their  production  can  be
influenced by many environmental factors.(16,109)
TGF- is one of the most prominent EMT inducing cytokines that activates a wide array
of transcription factors.(97)  TGF- signaling activates ras-dependent and Smad-dependent
mechanisms and these promote the translocation of the Smad complex into the nucleus
where it then activates EMT-RTFs.(16,110) TGF- binding initiates Par6 phosphorylation
and the activation of the E3-ubiquitin ligase, Smurf-1. The activated Smurf-1 promotes the
degradation of RhoA, resulting in tight junction dissociation and the blockering of cell
adhesion.(16) Par6 phosphorylation also causes the loss of apical-basal polarity.(96)
FGF receptor activation switches on two different pathways, Src and Ras. Src activation
phosphorylates cytoskeleton-associated proteins, adherens junction proteins and focal
adhesion components. The Ras pathway activates mitogen-activated protein kinase
(MAPK) which is translocated to nucleus and thus can activate snai1 and slug. (13) Three
signaling  pathways  which  are  essential  for  stem  cell  function  and  early  embryogenesis,
namely Wnt/-catenin, Notch and Hedgehog signaling pathways, have also a major impact
on  EMT.(108)   MMPs  are  induced  by  TGF- and  are  capable  of  cleaving  E-cadherin  and
disrupting the cadherin-mediated cell-cell contacts thus promoting EMT.(16) In addition,
EMT processes often require the co-expression of integrin receptors.(15)  Integrins are cell-
surface receptors which link ECM to the intracellular actin cytoskeleton.(16) Integrins have
a dual influence on EMT process: they can induce E-cadherin downregulation and inhibit
E-cadherin mediated signals to integrins by activation of the small GTPase Rap1.(15)
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EMT  is  also  regulated  by  multiple  environmental  factors.(98,109)  The  influence  of
inflammatory components on the regulation of EMT has been highlighted recently. For
instance  the  induction  of  snai1  through  the  cyclo-oxygenase2  (COX2)  pathway  as  well  as
the  induction  of  snai1  and  zeb1  through  nuclear  factor  B  (NF-B)  and  by  some
interleukins has been reported.(111,112) By secreting TGF-, tumor associated macrophages
provoke snail overexpression via NF-B activation.(109) Furthermore it is known that
hypoxia  promotes EMT by direct stimuli of transcription factors via hypoxia-inducible
factor-1 (HIF 1). (16,97)
There is a significant cross-talk between the EMT-inducing signals and transcription
factors  that  can  lead  to  stable  reprogramming  of  epithelial  cells  to  mesenchymal
states.(96,113). There is also a growing understanding of the epigenetic regulation of EMT
involving three types of changes: DNA methylation, histone modifications and micro-
RNAs (miRNA).(114) Each of these mechanisms has been have shown to play a major role
in  controlling  EMT.  MiRNAs  are  short  non-coding  RNAs  that  repress  gene-expression  at
the post-transcriptional level. Some miRNAs are reduced in tumors as compared to normal
tissue and they have been shown to restrain the EMT process. The miR-200 family inhibits
the  repressors  of  E-cadherin  and  thus  helps  in  maintaining  the  epithelial
phenotype.(105,113,115) In contrast, some miRNAs like miR21, miR25 and miR31 facilitate
EMT by downregulating tumor suppressor genes .(101,105,113)
 Figure 5. Overview of  the  signaling  pathways  that  regulate  EMT.  (Thiery  and  Sleeman 2006,
reprinted by permission of publisher)
2.3.4 EMT and epithelial-stromal interaction in cancer progression
Tumor progression and the formation of metastases involve several distinct steps:
emigration of tumor cells from the primary tumor, penetration through basement
membrane,  invasion  into  neighboring  tissues  and  into  blood  or  lymphatic  vessels,  cell
survival  detached from the tumor mass, extravasation, formation of the micrometastatic
nodule as well as adaptation and reprogramming of the surrounding stroma to form
macrometastases (Fig. 6).(116) Tumor cells are capable of going through those steps by
adopting the mesenchymal phenotype. The manipulation of E-cadherin has a dual effect on
tumor progression. Firstly, the loss of E-cadherin disrupts adhesion junctions which allow
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the  detachment  of  malignant  cells  from  the  epithelial-cell  layer.  Secondly,  the  loss  of  E-
cadherin has direct effects on signaling pathways, including the Wnt signaling pathway
and  Rho-family  GTPase  mediated  modulations,  involved  in  tumor  cell  migration  and
tumor growth.(16) Tumorigenic processes involve genetically abnormal cells that
progressively lose their responsiveness to normal growth-regultory signals.(96) Tumor
tissues typically lack the coordinated and orderly induction of a complete EMT and the
EMT markers are only present in a certain part of tumor tissue and cells. This might be due
to the presence of genetic heterogeneity within the tumor and highly variable
environmental signals.(117) In the absence of growth factors that actively promote the
induction and continued expression of EMT derived by activated stroma, cells will revert
back to the epithelial state. MET is believed to be involved the in formation of distant
metastases by this mechanism.(96,109,113)
Figure 6. EMT and MET in the emergence and progression of carcinoma. During tumor
progression, epithelial cells gain mesenchymal features by EMT which enables them to emigrate
from the primary tissue, penetrate through the basement membrane and enter into the blood or
lymphatic vessels. At the metastatic site, they extravasate and form metastases by
MET.(Modified from Thiery 2002)
There  is  solid  evidence  to  suggest  that  EMT  plays  a  significant  role  during  tumor
progression.  The  expression  of  mesenchymal  markers  as  well  as  the  loss  of  epithelial
markers correlate with tumor progression and a poor prognosis in multiple
carcinomas.(113,118-120) Genetic analyses have revealed that carcinoma cells contribute to
the stromal-fibroblast population in tumors indicating that tumor cells have gone through
EMT.(121-123) However, the in vivo demonstration of EMT has turned out to be challenging
due to heterogeneity of the tumors, the phenotypic complexity within tumor cells and the
reversible nature of EMT.(98)
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 The cross-talk between the microenvironment and the tumor cells has been emphasized
in  recent  studies.(98,109,124)  The  behavior  of  carcinoma  is  influenced  by  the  tumor
microenvironment consisting of ECM, diffusible growth factors and cytokines, blood
vasculature, inflammatory cells and fibroblasts. Normal stroma contains a low number of
fibroblasts in association with a physiological ECM. Instead, activated stroma has an
increased number of fibroblasts, enhanced capillary density and type-1-collagen and fibrin
deposition.(125) This reactive stroma provides oncogenic signals to facilitate tumorigenesis.
In the absence of aberrant microenvironmental stimuli, the genetic and epigenetic
alterations in tumor cells are believed to be insufficient to induce tumor progression.(109)
An invasive tumor is often associated with the expansion of tumor stroma and increased
deposition of ECM and in many carcinomas the stroma comprises most of the tumor
mass.(12)
 Cancer cells can modulate their own microenvironment by producing stroma-
modulating growth-factors, which include basic fibroblast growth factor (bFGF), vascular
endothelial growth factor (VEGF), PDGF, EGF, interleukins and TGF. These factors act in
a  paracrine  manner  to  induce  angiogenesis  and  to  evoke  inflammatory  responses.  The
factors also activate surrounding stromal cells to secrete additional growth factors and
proteases.(12,124,126)  Activated fibroblasts are an important sources of ECM-degrading
proteases such as MMPs.(125) The cancer cells also start to produce proteolytic enzymes,
which  remodel  ECM  and  the  basement  membrane  provoking  pro-invasive  and  pro-
migratory environment.(12) Carcinoma associated fibroblasts (CAF) are fibroblasts that
have  been  modulated  by  the  influence  of  neighboring  tumor  cells.(127)  They  are
mesenchymal cells that share the characteristics of fibroblasts and smooth-muscle cells and
are often identified by the expression of -smooth muscle actin.(128) The presence of CAFs
in activated stroma has been observed in many cancer types.(128,129) It is believed that the
oncogenic signals from the CAFs can stimulate the progression of epithelial cells into their
tumorigenic counterparts by expressing a range of cytokines and growth factors, promoting
tumor-cell survival and migration.(12,98) CAFs also further activate tumor stroma by
stimulating angiogenesis and recruiting inflammatory cells (Fig. 7).(11)
EMT may also lead to the formation of stromal cells in addition to solitary invasive
carcinoma cells.(13) These non-tumorigenic carcinoma-derived fibroblasts have displayed a
remarkable property of enhancing tumorigenity in mice since they possess both tumor
growth and EMT promoting properties.(16,98,122) Furthermore, tumor associated
macrophages, representing a major component of the tumor microenvironment, can
promote EMT by producing TGF-.(98) Many  factors  favoring  EMT  in  carcinomas  are
components of heterotypical signaling pathways which originate in the tumor-associated
stroma.(96,130) Although there are several of these microenvironment derived signals, Wnt
and TGF have been the most extensively studied. EMT and endothelial-mesenchymal
transition (EndMT) are ways for converting epithelial and endothelial cells into fibroblast-
like  cells  with  an  altered  genome.(125)  However,  according  to  the  genetic  studies,  only  a
fraction of the CAFs are derived from EMT.(122)
Hypoxia,  often  present  in  large  tumor  masses,  can  induce  EMT  in  tumors  through
multiple distinct mechanisms including upregulation of HIF1, activation of the Notch or
NF- B pathways or direct activation of snai1 and twist.(96,109)
In addition to promoting invasion and metastatic dissemination, EMT contributes to the
acquisition  of  therapeutic  resistance  of  cancer  cells  by  protecting  cells  from  drug-  and
radiation -induced apoptosis and cell death.(131,132) In a breast cancer cell line, EMT was
found to be involved in mediating multidrug resistance (MDR).(133)
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Figure 7. Crosstalk  between  tumor  cells  and  their  activated  stromal  surroundings.  (Modified
from Mueller 2004)
2.3.5 EMT related transcription factors (EMT-RTFs)
A hallmark of EMT is the loss of the adherens junction protein E-cadherin. Only a small set
of transcription factors regulate E-cadherin expression directly at the transcriptional level,
namely  the  snail  and  zeb  –families  of  zinc  finger  proteins  along  with  the  twist  family  of
basic helix-loop-helix (bHLH) factors. All of these factors bind to two high-affinity binding
sites,  CAGGTG  E-box  sequences  located  in  the  E-cadherin  promoter  region.(17-20)  These
transcription factors were originally identified as regulators of embryogenesis and were
only  later  recognized  to  have  significant  roles  also  in  cancer  progression.(134)  EMT-RTFs
do  not  simply  repress  E-cadherin  but  are  able  to  orchestrate  the  entire  EMT  program  by
inhibiting and activating a wide array of epithelial and mesenchymal genes. There is often
very  marginal  expression  of  EMT-RTFs  is  in  normal  tissues  but  this  level  increases  with
malignant transformation.(135,136)
2.3.5.1 Snai1 and Slug
Snai1 was first identified in Drosophila where it downregulates E-cadherin to control
gastrulation.(137)  To date, three members of snail superfamily have been described; snai1
(originally  identified  as  snail),  snai2  (also  known  as  slug)  and  snai3  (smuc).  These  all  are
zinc-finger  transcription  factors  sharing  a  common  structure,  i.e.  a  highly  conserved  C-
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terminal  region,  four  to  six  zinc  fingers  and  a  divergent  amino-terminal  region  (Fig.
8).(112,138) Snail-deficient mouse embryos fail to gastrulate which eventually leads to
death  of  the  embryos.(139)  Snail  genes  are  also  involved  in  mouse  and  chick  palatal
fusion.(140)  During  tumorigenesis,  snai1  has  several  cellular  functions  in  addition  to  the
direct repression of E-cadherin. It down-regulates other epithelial markers but, on the other
hand activates the expression of some mesenchymal-like and pro-invasive genes.(141,142)
Snai1 expressed cells are resistant to direct apoptotic stimuli and to DNA damage and they
also promote angiogenesis.(21,22) Snai1 may also accelerate metastasis through
immunosuppression.(143)
Figure 8. Main  structural  domains  of Snai1 and Snai2 (Peinado 2007, reprinted by the
permission of publisher)
The  transcriptional  activation  of  snai1  is  mediated  by  several  pathways  including  TGF-,
Notch  and  WNT-pathways  as  well  as  hypoxia.  it  is  known  that  TGF- can  induce  the
activity  of  snai1  promoter  and  triggers  EMT  by  a  mechanism  dependent  on  mitogen-
activated protein kinase (MAPK) signaling pathway.(144) Notch signaling induces snai1
directly by activating its promoter and indirectly through HIF-1 mediated activation.
WNT  signaling  can  increase  snai1  function  by  preventing  its  nuclear  export  and
degradation. On the other hand, snai1 can promote WNT signaling by ensuring that E-
cadherin  remains  downregulated  thus  making  -catenin  available  to  promote  WNT
signaling.(119)
     At the posttranscriptional level, the activity of the snai1 protein is regulated by
phosphorylation, which in turn influences its subcellular localization. Snai1 is a very
unstable protein and it is considered to be active only when it is localized in the
nucleus.(145) There are at least five kinases that can phosphorylate snai1 protein  in distinct
regions.(97) Glycogen-synthase kinase-3 (GSK3) phosphorylates two Ser residues on
snai1,  one  of  which  targets  snai1  for  ubiquination  and  degradation,  whereas  the  other
promotes its nuclear export.(145) Mutations in GSK3-mediated phosphorylation produce
a  stabilized  form  of  snai1  that  becomes  localized  in  nucleus  and  promotes  EMT.(15)
Activation of  EGF receptor signals to snai1 through p21-activated kinase-1 (PAK1). PAK1
phosphorylates  snai1  on  a  different  Ser  residue  than  GSK3 which  also  results  in  snai1’s
accumulation within the nucleus. Additional protein modifications by lysyl oxidases 2 and
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3 further stabilize snai1 protein and promote EMT as well as tumor invasion.(146)
Proinflammatory cytokine tumor necrosis factor  (TNF) stabilizes snai1 through the NF-
B pathway thus promoting inflammation-mediated metastases in breast cancer.(147)
There  is  a  report  that  Snai1  mediates  MMP-induced  EMT(104),  and  it  also  indirectly
upregulates MMP2.(142) Snai1 can bind to and repress its own promoter, evidence for the
presence of an autoregulatory loop.(112) Snai1 is repressed by MiR-29b and let-7d, MiRNAs
that block EMT and invasiveness in HNSCC. Members  of  the  miR-30  family  also  target
snai1.(134)
Snai1 overexpression correlates with tumor progression in breast, endometrial and
ovarian carcinomas.(148-150) Its expression in tumor stroma but not in epithelium
correlates with tumor progression, metastasis and patient survival in colorectal tumors.(29)
There  are  only  a  few  studies  examining  snai1  expression  in  HNC.  Snai1  expression  in
HNSCC  predicted  metastases  but  did  not  correlate  with  the  levels  of  p16  or  EGRF
expression.(151)  In  oral  SCC,  snai1  was  mainly  detected  in  tumor  stroma  and  in  some
endothelial cells but displayed no correlation with the histological grade or nodal
metastasis.(37) In laryngeal carcinoma, the nuclear or cytoplasmic expression of snai1 was
associated with local recurrence.(28) Snai1 overexpression in HNSCC correlated with
metastases and worse prognosis.(152) In a recent study of nasopharyngeal carcinoma,
nuclear expression of snai1 predicted poor survival while cytoplasmic expression had no
correlation with any of the studied clinicopathological variables.(153)
Slug is involved in neural crest development of chicken and Xenopus embryos.(138) Slug
deficient mice are viable but slow-growing and display craniofacial malformations as well
as coloring defects.(154) In humans, slug-mutations are connected to the Waardenburg
syndrome with deafness and impaired melanocyte function.(155) Slug expression promotes
E-cadherin downregulation, although slug is a much weaker repressor of E-cadherin than
snai1.(156) Slug expression is not always associated with E-cadherin downregulation but it
may  act  synergistically  with  other  E-cadherin  repressors.(157)  Slug  expression  also
promotes programmed cell death.(23) TGF1 increases slug levels in malignant oral
SCC.(158)   In  that  study  induction  of  slug  did  not  repress  E-cadherin  levels  but  instead
increased MMP-9 expression. Slug is a molecular target of transmembrane tyrosine kinase
receptor  c-kit  signaling  pathway.(159)  In  addition,  Wnt  signaling  upregulates  slug  and
promotes E-cadherin repression.(160) Exogenous slug expression in HNSCC cells causes
changes  in  the  assembly  of  the  adherens  junction  and  the  desmosome  characterized  by  a
classical cadherin switch.(161) Slug downregulation promoted apoptosis and decreased
invasion capability in esophageal SCC.(162) Slug antagonizes p53 mediated apoptosis in
haematological precursors.(163)  There is little knowledge about post-transcriptional
regulation of slug. However, the partner of paired (Ppa) protein modulates its stability and
degradation.(164) MiR-1 and MiR-200 inhibit slug expression and are repressed by binding
of slug to their promoters. Slug is also inhibited by MiR-203.(134)
In esophageal cancer, slug expression is related to lymph node metastasis, invasion and
poor prognosis.(30) In addition, in colorectal carcinoma, slug expression has been reported
to be  an independent  prognostic  factor  for  poor  survival.(165)  However,  in  oral  SCC slug
expression did not correlate with any investigated clinicopathological variable or
survival.(38)
2.3.5.2 Twist
Twist is a basic helix-loop-helix (bHLH) transcription factor consisting of two parallel -
helices joined by a loop which is required for dimerization. It  was first reported to play a
key role in mesoderm formation and proper gastrulation in Drosophila.(166) Twist is also
an important factor in mammalian embryogenesis. Mutational inactivation of the twist gene
is postulated to be responsible for the Saethre-Chotzen syndrome which is an autosomal
dominant  disorder  characterized  by  the  premature  fusion  of  cranial  sutures,  skull
deformation, limb abnormalities and facial dysmorphisms.(167) Twist expression is
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upregulated by EGF and transcriptionally regulated by an oncoprotein STAT3.(168)
Hypoxia and HIF-1 also induce twist upregulation and at the same time twist is critical in
hypoxia-induced  EMT.(169)  NF  B  has  been  implicated  in  EMT  since  it  can  promote
expression of twist.(110) At the post-transcriptional level, p38 kinase mediated
phosphorylation regulates the homodimerization and DNA binding capacity of twist while
p42 and p44 kinases are involved in twist degradation in response to Notch signaling.(112)
Several  miRNAs  have  been  reported  to  target  twist,  including  miR-214,  miR-580  and  let-
7d.(97)
     Twist induces EMT by promoting the downregulation of E-cadherin and several catenins
but  also  by  upregulating  mesenchymal  markers.(20).  Yang  et  al  linked  twist  to  the  early
phases of metastasis formation, namely tumor cell intravasation. Although twist was highly
expressed in metastatic cell line its suppression did not affect cell proliferation and tumor
formation  but  it  did  reduce  significantly  lung  metastases  from  a  mouse  mammary  gland
tumor model.(20,170) A recent study reported that activation of twist was sufficient to
promote carcinoma cells to undergo EMT and disseminate into blood circulation.(171)
Twist has also been shown to possess antiapoptotic properties. It inhibits oncogene-
dependent cell death and it bypasses p53-induced growth arrest thus facilitating tumor
progression.(24) Twist also allows cancer cells to override premature senescense and it co-
operates with oncoproteins such as Ras and ErbB2 to promote complete EMT.(172) Bmi1, a
polycomb-group repressor complex protein, which is often upregulated in stem cells and
cancer seems to be a direct downstream target gene of twist. (97,173) Upregulation of twist
has been also associated with cellular resistance to the taxol and vincristine, two important
anticancer drugs.(174) The resistance is mediated through twist-induced protection against
apoptosis being regulated through Akt phosphorylation.(175) Akt, a known proto-oncogen,
is a downstream target of twist, which binds to the E-boxes on its promoter and
transactivates its expression.(176) Twist can also exert its downstream effects in cancer cells
through the modulation of several MiRNAs. (177)
     Twist is absent in normal epithelium but is known to be induced in several human solid
tumors. Twist expression significantly shortened the metastasis-free period in one HNSCC
series(169) and in another HNSCC trial, the extent of twist expression correlated with a
higher  frequency  of  lymph  node  metastases  as  well  as  tumor  progression.(178)  Twist
overexpression has been associated with aggressive tumor properties and poor survival
also  in  oesophageal  and cervical  SCC.(31,33)  However,  in  a  recent  study of  oral  SCC,  the
extent of twist expression did not correlate with any clinicopathological variables or
survival.(179) Twist was postulated to mediate taxol resistance through protection against
apoptosis in nasopharyngeal carcinoma.(174,175)
2.3.5.3. Zeb1 and Sip1
The human zeb family of transcription factors consists of two members, zeb1 (Zinc-finger
E-box  binding  homeobox  1,  also  known  as  TCF8  and  EF1)  and  zeb2  (Smad  interacting
protein  1,  sip1,  also  known  as  ZFXH1B).  These  proteins  are  highly  homologous  and  are
characterized  by  two  clusters  of  zinc  fingers  separated  by  a  homeodomain.(18)  During
embryogenesis, zeb1 influences the development of neural, chondroid and
haematolymphoid tissues.(180) Sip1 is expressed in embryonic neural crest cells and the
neural  tube  and  is  responsible  for  the  fate  of  neuronal  progenitor  cells  as  well  as  the
myelination of the central nervous system. (18) (181) Sip1 is also critical for neural crest
epithelial sheet formation.(182) Zeb family members were  initially found to be mutated in
developmental diseases including Hirschsprung’s disease and posterior polymorphous
corneal dystrophy.(183,184)
     While zeb1 and sip1 have many overlapping characteristics, they still display distinct
expression patterns. TGF factors induce both zeb molecules which bind to Smad proteins
and antagonistically regulate their transcriptional properties; zeb1 activates smad-mediated
transcription whereas sip1 represses it.(185) Zeb1 is induced by TGF1, NF- B  and the
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notch signaling pathways.(115,186) Zeb molecules are believed to act as either
transcriptional repressors or activators depending on the target gene and tissue as well as
on posttranscriptional modifications.(187) Zeb1 and sip1 are repressed by miR-200 family
and  miR-200  family  members,  in  turn,  can  be  repressed  by  zeb-proteins,  thus  forming
regulatory loops maintaining cells in either the epithelial or mesenchymal states.(105,115).
Overexpression of  miR-200 ensures  the  maintenance of  epithelial  traits,  inhibits  EMT and
reduces  tumor  invasion.  Surprisingly,  however,  elevated  miR-200  can  also  promote
metastatic colonization and be present in malignant cancer stem cells.(97,113)
In addition to downregulating E-cadherin, zeb1 also affects epithelial cell polarity by
downregulating  several  polarity  markers  and  by  inducing  the  selective  loss  of  basement
membrane  components.(25,26)  Since  it  is  an  inhibitor  of  the  epithelial  phenotype,  zeb1  is
not expressed in normal epithelium, although it is found in isolated fibroblasts and
immune  cells  in  the  interstitial  stroma.(134)  However,  zeb1  is  highly  expressed  in  the
invading  cancer  cells  of  many  tumors.  Spoelstra  et  al  discovered,  that  zeb1  was  not
expressed in normal endometrial epithelium but overexpressed in malignant epithelium
and also in tumor-associated stroma.(188) In gastric carcinoma, zeb1 overexpression
correlated with higher TNM class, deeper invasion and lymph node metastases.(189) Zeb1
overexpression  predicted  also  larger  tumor  size,  metastases  and  poorer  survival  in
hepatocellular carcinoma patients.(190) However zeb1 expression did not correlate with
survival in either patients with lung tumors(191) or bladder carcinoma.(39)
Sip1 downregulates E-cadherin transcription by binding to the e-boxes of its promoter.
The level of sip1 expression is elevated in fibroblasts and invasive carcinoma cell-lines and
the extent of the expression strongly and inversely correlates with E-cadherin
expression.(19) Sip1 expression also downregulates the major constituents of different cell
junctional complexes such as tight junctions, adherens junctions, desmosomes and gap
junctions.(180) Furthermore, sip1 exerts an anti-apoptotic effect on the response to combat
DNA damage.(27) Sip1 expression has also been shown to induce several MMPs, especially
MMP2.(192) Its post-transcriptional regulation is organized by proprotein convertase 2 -
mediated sumoylation of sip1 which prevents its interaction with c-terminal binding
protein by promoting its cytoplasmic localization. The functional consequences of this
process  for  protein  stability  remain  to  be  clarified.(112)  The  amount  of  expression  and
subcellular localization of sip1 varies considerably between different tissues and tumor
types.(193)  In  a  study of  47  OSCC samples,  the  expression of  sip1  was detected in  tumor
epithelium and stromal cells in 28% of the samples and it  exhibited an inverse correlation
with  E-cadherin  expression.  In  that  study,  sip1  expression  proved  to  be  an  independent
prognostic factor for poor DSS.(34) Furthermore, in tongue SCC, sip1 expression correlated
with E-cadherin repression and predicted vascular invasion as well as delayed
lymphonodal metastases.(194) In bladder cancer, the sip1 expression was found to
represent  an  independent  predictor  of  poor  DSS  and  preserved  cells  from  DNA-damage-
induced apoptosis thus protecting cancer cells from radiation.(27) In addition, sip1
expression predicted lower OS in lung cancer.(195)
2.3.6 Cooperation between EMT-RTFs
All  the  above-described  transcription  factors  induce  EMT  by  repressing  E-cadherin  and
other  epithelial  markers  and  by  enhancing  the  expression  of  mesenchymal  proteins.(113)
Why are there so many distinct transcription factors involved? One reason may be that they
are activated in many different steps of embryogenesis and their expression depends on a
diverse array of contextual signals which are present in different tissues and act in various
stages of development. Another explanation is that none of these transcription factors can
regulate the EMT on their own but they are expressed in various combinations in different
cell  and  cancer  types.(196)  Snai1  could  be  considered  as  an  early  marker  of  EMT  and  it
sometimes contributes to the induction of the other factors. In contrast, slug, zeb1, sip1 and
twist may be responsible for the maintenance of the migratory cell behavior and other
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tumorigenetic properties.(112) Knockdown experiments in several cancer lines with the co-
expression of EMT-RTFs have shown that ablation of only one transcription factor may be
sufficient to block EMT, either partially or even totally.(113)
TGF has been considered as a key molecule in orchestrating the interplay of EMT-RTFs
in tumor progression.(107) Sip1 mediated E-cadherin repression doues not seem to be
dependent on snai1 expression but instead snai1 could be an upstream mediator of TGF-
induced zeb1 expression.(18,19) Snai1 increases zeb1 protein levels through both
transcriptional and post-transcriptional mechanisms and the protein can exist in its induced
level for several weeks after snai1 has been eliminated.(134,197) In addition, slug activates
zeb1 by direct binding to its promoter. Twist needs a direct transcriptional induction of slug
to promote EMT. Slug knockdown completely blocks the ability of twist to suppress E-
cadherin transcription and the entire EMT process.(198)
As a sign of the interaction between EMT-RTFs in different human cancers, there is often
enhanced tumor progression and poorer prognosis, when several EMT-RTFs are expressed
simultaneously.  The  co-expression  of  snai1,  twist  and  HIF-1 in  HNSCC  correlated  with
metastases and poorer prognosis as compared with expression of only one or two markers.
(169) Furthermore, in hepatocellular carcinoma and in non-small cell lung cancer, snai1 and
twist co-expression predicted lower survival.(35,36) Co-expression of twist2 and sip1
together with HIF-2 correlated with a higher risk for distant metastases and a lower
survival rate in patients with adenoid cystic carcinoma of the salivary gland.(199)
2.3.7 Endothelial-mesenchymal transition (EndMT)
EndMT, analogous to EMT, is characterized by delamination of endothelial cells from the
organized cell  layer  and the  acquisition of  mesenchymal  markers  as  well  as  invasive  and
migratory properties. During embryogenesis EndMT is important in the organization of the
endocardial cushion and heart valves.(101) The endothelial cells associated with tumor
microvasculature can also contribute to the formation of mesenchymal cells via EndMT.
Mouse  endothelial  cells  can  acquire  a  fibroblast-like  phenotype  when  exposed  to
TGF.(200) EndMT can also be modulated by Notch pathway.(201) Angiogenic vessels can
undergo  EndMT  and  thus  it  may  play  an  important  role  in  stabilizing  neovasculature
during  angiogenesis.(201)   It  has  been  postulated  that  EndMT  is  an  important  source  of
carcinoma associated fibroblasts. Indeed, endothelial cells are believed to contribute to the
accumulation of fibroblasts within the microenvironment of angiogenic tumors.(200)
2.3.8 Cancer stem cells (CSC)
EMT can be manifested in only a subset of tumor cells, often located at the invasive front of
the tumor, and the adjacent stromal cells.(202) These cells may be referred to as CSC with a
particular propensity for invasion and metastases.(11,203) CSCs are considered to be a
subpopulation of tumor cells capable of regenerating the entire tumor with metastatic
properties.(204) They remain in a quiescent state thus becoming resistant to chemo- and
radiation  therapies  and  therefore  they  play  an  important  role  in  cancer  relapses  and
metastases.(204,205)  However,  the  existence  and  significance  of  CSCs  is  still  rather
controversial.
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3 Aims of the Study
Despite the recent advances in cancer diagnostics and treatment, PSCC still has a poor
prognosis. Concurrently, the incidence of PSCC is increasing. Until now, the prognosis of
the patient and selection of the treatment modality has been determined mainly by clinical
factors. To improve the diagnostics and thus also the treatment of the patients, more
specific prognostic markers will be needed. EMT is a well characterized phenomenon
providing potential predictors for tumor behaviour but it has not been studied in PSCC.
The specific aims of this study were:
1. To analyse the prognostic value of clinical variables in the current PSCC material (I-
III)
2. To examine the expression of transcription factor snai1 and its effect on the
prognosis in PSCC (I)
3. To evaluate the expression and prognostic role of twist in PSCC (II)
4. To investigate sip1, zeb1 and slug expression and their influence on survival in
PSCC (III)
5. To assess the co-expression of EMT-RTFs and its prognostic value in PSCC (II-III)
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4 Patients, materials and methods
4.1 Study design
This study was a retrospective, longitudinal research with population-based cohort design.
The primary cohort incorporated all patients diagnosed with PSCC between the years 1975
and 1998 in the Area of Regional Responsibility of the Kuopio University Hospital
including  Central  Hospitals  of  Central  Finland  (Jyväskylä),  Northern  Karelia  (Joensuu),
Southern  Savo  (Mikkeli)  and  Eastern  Savo  (Savonlinna)  together  with  Kuopio  University
Hospital. The patients were identified from the hospital records and the Finnish Cancer
Registry  (www.cancerregistry.fi).  Initially  there  were  a  total  of  161  patients  fulfilling  the
criteria. The mean population in the district during the study-period was 870 000.
4.2 Clinical data and Follow-up
The  clinical  data  from  all  161  patients  were  reviewed  by  one  oncologist  and  two
otolaryngologists. Ten cases had to be excluded because the cancer had originated outside
the pharyngeal area or because of insufficient clinical data. The remaining 151 tumors were
staged according to the UICC classification (1997), based on written hospital records of
clinical otolaryngological status, endoscopy and chest x-ray.(206) Karnofsky performance
status (KPS) at the time of diagnosis was coded according to the case history. All the
patients had been regularly followed up by an otolaryngologist and/or oncologist until
death or April 2009. The cause of death was obtained from hospital records or from death
certificates. None of the patients was lost from the follow-up.
4.3 Tumor samples and histopathology
All  tissue  samples  available  were  retrieved  from  the  archives  of  each  hospital.  They  had
been all originally fixed in 10% formalin (buffered, pH 7.0) and embedded in paraffin. Of
the 151 cases 138 were histologically verified invasive squamous cell carcinomas of oro- or
hypopharyngeal origin for which sufficient clinical data was available. All the sections were
evaluated and histological differentiation of the primary tumor was determined according
to the WHO criteria by one experienced pathologist.(52) Sufficient material for tissue
microarrays and immunohistochemical analyses were available from 110 original tumor
samples for snai1 staining, 109 for twist staining and 108 for sip1, zeb1 and slug stainings.
4.4 Tissue microarray and immunohistochemistry
Two most representative areas of the paraffin-embedded tissue blocks were chosen by an
experienced pathologist (V-M Kosma or Y Soini) and marked for microarrays which were
constructed using 1.0 mm core Manual tissue arrayer I (Beecher Instruments, Silver Spring,
MD,  USA).  Four-μm-thick  sections  were  first  deparaffinized  and  rehydrated  in  a  routine
manner. Then the sections for snai1 analysis were heated in a microwave oven (800W) for 2
x 5 minutes in Tris EDTA buffer (pH 9.0) and the other sections in 0.01 molar citrate buffer
(pH 6.0) for 2 or 3 x 5 minutes (3 for twist, two for sip1, zeb1 and slug), incubated in the last
buffer for 18 minutes and washed twice for 5 minutes in phosphate buffered saline (PBS).
Endogenous peroxidase activity was blocked with hydrogen peroxide (5%, 5 minutes)
followed by washing with water 2 x 5 minutes and with PBS for 2 x 5 minutes. Non-specific
binding  was  blocked  with  1.5%  normal  serum  in  PBS  for  25-35  minutes  at  room
temperature.  All  the  sections  were  incubated  overnight  at  4°C  with  specific  antibodies  as
indicated in table 4. In the negative controls, the primary antibody was omitted. The slides
were  then  washed  with  PBS  for  2  x  5  minutes.  Snai1,  twist,  sip1  and  zeb1  stained  slides
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were incubated with the biotinylated secondary antibody (ABC Vectastain Elite Kit, Vector
Laboratories, Burlingame, CA, USA) for 35 minutes at room temperature. Thereafter, the
slides  were  washed  twice  in  PBS  for  5  minutes,  incubated  for  45  minutes  in  preformed
avidin-biotinylated peroxidase complex solution(ABC Vectastain Elite Kit, Vector
Laboratories,  Burlingame,  CA,  USA)  and  washed  with  PBS  for  2  x  5  minutes.  In  slug
sections, Dako REALtm EnVision tm secondary antibody (K5007) was used and incubated
slides for 30 minutes. The color was developed by diaminobenzidine tetrahydrocloride
(DAB)  (Sigma,  St.  Louis,  MO,  USA).  The  samples  were  counterstained  with  Mayer's
haematoxylin,  washed,  dehydrated,  cleared  and  mounted  with  Depex  (BDH,  Poole,  UK).
Ovarian tumor tissue with known positive expression was used as a positive control for
snai1.  Strongly  positive  pharyngeal  tumor  tissue  samples  for  twist,  slug,  sip1  and  zeb1
antibodies were identified in preliminary test stainings and were then used as positive
controls in each definitive staining series.
Table 4. Specific antibodies used for immunohistochemical stainings
Marker
Number of
cases Primary antibody Manufacturer Dilution
snai1 110
mouse monoclonal anti
snai1
non-commercial,
(207,208) 1:750
twist 109
mouse monoclonal anti
twist
Abcam, Cambridge,
UK 1:100
sip1 108 rabbit polyclonal anti sip1
Santa Cruz Biotech.
Inc, Dallas, USA 1:200
slug 108 rabbit polyclonal anti slug
Abnova, Taipei City,
Taiwan 1.100
zeb1 108
mouse monoclonal anti
zeb1
GenWay Biotech. Inc,
San Diego, USA 1:500
4.5 Evaluation of the expression
All the array spots were separately evaluated by two or three observers: A Jouppila-Mättö,
H  Tuhkanen  and  Y  Soini  for  snai1,  A  Jouppila-Mättö,  R  Sironen  and  Y  Soini  for  twist,  A
Jouppila-Mättö  and Y Soini  for  sip1 and slug and A Jouppila-Mättö  and R Soini  for  zeb1.
The observers were unaware of the clinical and histopathological data. The number of snai1
immunostained tumor epithelial, stromal and endothelial cell nuclei was counted on a
continuous scale, tumor epithelial cell nuclei from two spots and stromal and endothelial
cell nuclei from one array spot. In twist, sip1, slug and zeb1 array spots, the percentage of
stained tumor epithelial and stromal cell nuclei was counted and classified into 5
categories: 0-5%=1, 6-25%=2, 26-50%=3, 51-75%=4, 76-100%=5. The number of array spots
with detectable endothelial cell nuclear positivity was counted in sip1, slug and zeb1
stainings  and marked as  2  if  both spots  were  positive,  1  if  one spot  was positive  and 0  if
there were no positive endothelial cell nuclei present. In sip1 and slug samples, also
cytoplasmic staining in tumor epithelia and stromal tissue was observed. It was classified
into 4 groups: no staining=0, weak staining=1, moderate staining=2, intense staining=3. In
the classified variables, the observers evaluated together all of these spots where the scores
were diverging by more than one class in order to reach a consensus. The mean value
between the two array spots was then calculated. For continuous variables, the
interobserver agreement was evaluated by the Spearman test. The median value of every
variable was counted and the samples were divided accordingly into positive and negative
subgroups. All the median values are represented in table 5.
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Table 5. Median values of the positive imunohistochemical stainings
snai1(continuous
scale)
twist
(classified) sip1(classified) slug(classified) zeb1(classified)
Tumor
epithelial cell
nuclei 2 1.0 1.0 2.25 0.5
Tumor
stromal cell
nuclei 3 2.0 2.0 1.75 3.0
Endothelial
cell nuclei 7 - 1.0 1.0 1.0
Tumor
epithelial or
stromal
cytoplasm - - 1.25 2.1 0
4.6 Statistical analyses
Descriptive statistics were used for continuous variables, i.e. means with standard
deviations were used for normal distribution whereas medians with ranges were used for
values with non-normal (skewed) distribution, respectively. Mann-Whitney test was used
to examine the associations between continuous variables. Statistical associations between
classified variables were tested with the chi-square (2) test for independence. Frequency
tables with three variables were calculated with one-way ANOVA –test. Spearman’s
nonparametric rank order correlation coefficient was used to test the linear association
between non-normal variables. The disease specific survival was defined as the time period
between  the  date  of  primary  diagnostic  biopsy  and  the  date  of  death  due  to  pharyngeal
cancer  or  to  the  end  of  follow-up;  overall  survival  due  to  death  of  any  cause.  Univariate
survival analyses were evaluated using the Kaplan-Meier method. The statistical
differences between the curves were analyzed using the log-rank test. Multivariate survival
analysis was performed using Cox's proportional hazards model in a stepwise manner.
Values of p<0.05 were considered as significant. The statistical analyses were performed
using SPSS 14.0 software (SPSS Inc., Chicago, IL, USA).
4.7 Ethics
The research plan of the original research material had been approved by the ethical
committee of Kuopio University and Kuopio University Hospital (decision No 102/97), and
permission  for  accessing  data  from  the  Finnish  Cancer  Registry  and  from  the  hospital
records  was  obtained  from  the  Finnish  Ministry  of  Social  Affairs  and  Health  (permission
No 88/08/97). Due to the retrospective nature of the study, the patients or their families did
not need to be contacted. The data obtained have not been incorporated into hospital
records.
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5 Results
5.1 REMARKS ON COHORT AND TREATMENT
5.1.1 Patient and tumor characteristics
The summary of the clinical and histopathological data as well as treatment characteristics
are presented in table 6. The mean age of the patients at the time of diagnosis was 65 years
and three out of four patients were male. The median duration of the symptoms before
diagnosis was three months with the most prevalent prediagnostic symptoms being throat
pain, neck mass and dysphagia. According to the retrospective hospital records, 67 (62%) of
the patients were smokers and 53 (49%) had abundant alcohol consumption. The KPS score
coded at  the  time of  diagnosis  ranged between 40  and 90  and in  66% of  the  patients,  the
score was 70% or better. At the time of diagnosis most of the tumors (88%) were classified
as at least T2 and 43% of the patients presented with locoregional lymph node metastases.
Almost 70% of the tumors were diagnosed at an advanced stage (SIII-IV) and 76%
displayed moderate or a poor degree of differentiation. Sixty three percent of the tumors
were of orophrayngeal origin.
5.1.2 Treatment and follow-up
In  this  cohort  99  patients  received  radiotherapy  either  as  a  primary  treatment  (63%)  or
postoperatively as adjuvant therapy (28%). The median tumor dose of irradiation was 61
Grays (range 16-80). The primary tumor was operated in 36 cases (33%) and ipsilateral neck
dissection was performed in 18 patients (17%) The treatment was intended to be curative in
95 (87%) and palliative in 11 (10%) cases. Four patients received basic care only due to their
poor general condition. In 78 cases (72%), the treatment was successful while 31 (28%)
tumors did not respond.
     Complete  follow-up  data  were  available  for  the  whole  cohort.  Median  OS  was  20.9
months, 24.8 for oropharyngeal and 17.9 for hypopharyngeal carcinomas. Median DSS was
22.4 months (CI 12.7-32.2). The 5-years OS was 31.2% and DSS 41.3%. During five year
follow-up, there were 41 recurrences (38%) and 10 (9%) second primaries. In most cases,
tumors  relapsed at  the  site  of  the  primary tumor (n=22,  54%).  There  were  10  neck lymph
nodal (24%) and 9 distant relapses (22%). The median recurrence free period was 9.6
months (range 1.8 to 54.8 months). At the end of follow-up period, 67 patients (62%) had
died from pharyngeal carcinoma while only 10 (9%) were alive and diseasefree.
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Table 6 . Clinicopathological features of the patients with
pharyngeal squamous cell carcinoma ( n  = 108)
Variable n (%)
Mean age at the time of presentation, years 65 (std.dev. 10,5)
Median duration of the symptoms, months 3 [0-76]*
Sex
Male 81 (75)
Female 27 (25)
Site of primary tumor
Oropharynx 68 (63)
Hypopharynx 40 (37)
T category
T1 13 (12)
T2 39 (37)
T3 21 (19)
T4 35 (32)
N category
N0 62 (57)
N1 16 (15)
N2 27 (25)
N3 3 (3)
M category
M0 104 (96)
M1 4 (4)
Stage
S I 9 (8)
S II 24 (22)
S III 21 (19)
S IV 54 (50)
Histologic differentiation
Gr 1 25 (24)
Gr 2 48 (44)
Gr 3 35 (32)
Karnofsky performance status score
 70 % 71 (66)
< 70 % 37 (34)
Primary treatment
Radiotherapy 68 (63)
Surgery and radiotherapy 31 (28)
Surgery 5 (5)
No cancer specific treatment 4 (4)
Relapse
No 36 (33)
Yes 41 (38)
No response 31 (29)
Second primary tumor
No 98 (91)
Yes 10 (9)
Median OS, months 20.9 [1.1-401.3]*
*Values in square brackets indicate range.
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5.2 IMMUNOHISTOCHEMISTRY
5.2.1 Snai1
Snai1 expression was detected in epithelial, tumor stromal fibroblast and endothelial cell
nuclei of PSCC samples. Epithelial positivity was detected in 75 (68%) of the tumors. In all,
49 (46%) of tumor stromal cells and 51 (48%) of endothelial cells showed positive
immunostaining (Fig. 9). Stromal expression significantly associated with expression in
endothelium and epithelium (p-values <0.001) while expression in endothelium was related
to immunoreactivity in epithelium (p = 0.002). In less than ten samples, snail1 expression
was detected adjacent to necrotic and inflammatory areas. Cytoplasmic snai1 expression in
epithelium was present in only 4 (4%) of 110 samples. Snai1 protein expression in epithelial
cells was more abundant in tumors with hypopharyngeal origin (n=32, p = 0.044) and
patients with low KPS score (n=30, p = 0.039). The positive snai1 immunoreactivity in
epithelial cells predicted an earlier local relapse (p = 0.042). Stromal snai1 expression was
more common in hypopharyngeal tumors (n=23, p = 0.038), with increasing T category (T3-
4, n=31, p = 0.037), and in samples of patients with poorer general condition (KPS score < 70;
n=22, p = 0.039). In endothelial cells, positive snai1 immunoreactivity was related to
hypopharyngeal primary site (n=26, p = 0.01), increasing T category (T3-4, n=35, p = 0.005),
advanced stage (III-IV, n=44, p = 0.005) and poor histopathological differentiation (gr.2-3,
n=46, p = 0.012). No association was observed between snai1 immunoreactivity and age,
gender or neck lymph node metastases.
5.2.2 Twist
Twist expression was detected in tumor epithelial and stromal fibroblast cell nuclei.
However, the expression in stromal cell nuclei was more common than epithelial
expression (40% and 35%, respectively) (Fig. 10). Tumors with abundant stromal expression
relapsed  more  frequently  (p=0.04).  Stromal  expression  was  more  common  in
hypopharyngeal than in oropharyngeal tumors (p=0.015). Stromal expression of twist did
not correlate with patients’ age or gender, tumor size, stage, histological grade or smoking.
However, there was a tendency between stromal twist immunoreactivity and larger tumor
size (T3-4) and advanced stage (SIII-IV) (p=0.064 and p=0.086 respectively). In the current
cohort, epithelial expression of twist did not correlate statistically significantly with any of
the clinicopathological variables. However, patients with twist epithelial immunoreactivity
tended to have a worse general condition (KPS score < 70; p=0.077) and they also had more
neck lymph node metastases (p=0.099).
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Figure 9. Expression of transcription factor snai1 in pharyngeal squamous cell carcinoma.
Positive immunostaining in the nuclei of malignant epithelium (A), spindled stromal cells (B) and
the vascular endothelium (C). Lack of expression is also illustrated (D).  (Original magnification
of x 400, scale bar 100μm)
Figure 10. Expression of twist and snai1 nuclear transcription factors in pharyngeal squamous
cell carcinoma. Positive (A) and negative (B) twist immunostaining and positive snai1 staining
(C) in the spindled stromal cells (arrows). (Original magnification of x400)
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5.2.3 Sip1
Sip1 expression was abundant in tumor epithelial nuclei especially at the invasive front and
it was also frequently seen in tumor stromal fibroblasts and endothelial cell nuclei as well
as in the cytoplasm of all the cell types. Forty four of 108 (41%) samples showed epithelial
cell nuclear sip1 positivity and cytoplasmic positivity (41%).  The stromal cells were sip1
positive in 38 of 103 cases (37%) and 63 samples (58%) displayed positive endothelial cell
nuclei  (Fig  11).   There  was  also  a  correlation  between  sip1  cytoplasmic  and  nuclear
immunostaining (p<0001 for each cellular compartment). Furthermore, endothelial and
stromal nuclear stainings correlated statistically significantly (p<0.001). Tumors with
positive sip1 immunostaining in epithelial cell nuclei were more advanced (SIII-IV n=75,
p=0.02) and had more often lymph node metastases (N1-3 n= 46, p=0.04) as compared to
sip1  negative  tumors.  There  were  also  more  second  primaries  diagnosed  in  this  group
(n=10, p=0.048). Hypopharyngeal tumors were more often sip1 positive as compared with
oropharyngeal tumors (epithelial nuclei p=0.002, stromal nuclei p=0.03, cytoplasm p<0.001).
Better  differentiated  tumors  (grade  1-2  vs.  3)  had  often  positive  sip1  immunostaining  in
epithelial (n=36, p=0.006), stromal (n=30, p=0.048), endothelial (n=51, p<0.001) cell nuclei or
cytoplasm (n=35, p=0.02). Tumors with positive stromal staining of sip1 relapsed
significantly more often than sip1 negative tumors (n=32, p=0.007). (Table 7)
Table 7. Clinicopathological variables and sip1 expression (Significant values marked bold)
positive
epithelial
cell
nuclei,
cases
negative
epithelial
cell nuclei,
cases
p-value positive
stromal cell
nuclei,
cases
negative
stromal cell
nuclei,
cases
p-value
age <65 26 33 16 41
age >65 18 31 0.440 22 24 0.039
KPS score<70 16 21 17 19
KPS score70 28 43 0.702 21 46 0.111
gr. 1-2 36 36 30 39
gr. 3 8 28 0.006 8 26 0.048
T1-2 18 34 15 34
T 3-4 26 30 0.212 23 31 0.208
S I-II 8 25 9 22
S III-IV 36 39 0.021 29 43 0.278
N0 20 42 20 39
N1-3 24 22 0.037 18 26 0.466
M0 41 63 37 63
M1 3 1 0.155 1 2 0.897
oropharyngeal origin 20 48 18 45
hypopharyngeal
origin
24 16 0.002 20 20 0.028
remission 11 25 6 27
no remission or
relapse
33 39 0.128 32 38 0.007
no second primary 37 61 33 60
second primary tumor 7 3 0.048 5 5 0.366
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5.2.4 Slug
Tumor epithelial cell nuclear immunostaining of slug was apparent in 57 of 108 (53%) PSCC
tissue samples. Stromal fibroblasts nuclear staining was detected in 60 of 106 samples
(57%), tumor epithelial and stromal cytoplasmic in 55 of 108 array spots (51%) and 55% of
the  array  spots  showed  endothelial  nuclear  cell  positivity  for  slug  (54  of  98  samples)(Fig.
11). Tumors with positive slug expression in tumor epithelial nuclei located more often in
hypopharynx than in oropharynx (n=27, p=0.02).  In addition, slug positive tumors were
more often well or moderately differentiated (epithelial nuclei n=45, p=0.004; endothelial
nuclei n=41, p=0.049; cytoplasm n=43, p=0.01). Younger patients did not usually have slug
immunostaining in the stromal cell nuclei of the tumor samples (n=32, p=0.007).
5.2.5 Zeb1
Epithelial zeb1 immunopositivity was scarce. Thus, only single positive cell nuclei were
detected in 34 of 108 tumor samples (31%).  Stromal positivity was detected in 38 (35%) and
positive endothelial cells in 61 spots (56%). There was no cytoplasmic staining of zeb1 in
any  of  the  samples  (Fig  11).  Zeb1  immunoreactivity  did  not  correlate  with  any  of  the
clinicopathological variables.
Figure 11.   Immunohistochemical detection of sip1, slug and zeb1 in pharyngeal squamous cell
carcinoma.  Epithelial  (A  ,D,G),   stromal   (B,E,H)    and  negative  immunostainings   (C  ,F,I)  of
sip1,  slug and zeb1 respectively.  The stromal component includes endothelial and fibroblastic
cells (Original magnification of x200).
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5.2.6 Co-expression of snai1 and twist
A strong association between twist and snai1 expression in stromal cell nuclei was detected
(p=0.001, Spearman’s correlation coefficient 0.33) while in the epithelial cancer cell nuclei, a
similar association was absent (p=0.206, Spearman’s correlation coefficient 0.10). In
experiments  evaluating  tumors  undergoing  twist  and  snai1  related  EMT  a  group  was
selected  where  both  twist  and  snai1  were  positive  and  renamed  the  subgroup  as  EMT+
(n=29, 27%). All of these EMT+ tumors were at least Stage II (p=0.05) and were located more
often in hypopharynx (p=0.035). Twist and snai1 co-expression did not correlate with
histological grade, metastases or smoking habits. Respectively, tumors lacking both twist
and snai1 stromal immunoreactivity (n=42, 38.5%) were renamed EMT-. These tumors were
significantly smaller (T1-2, n=27, 64%, p=0.008), less advanced (SI-II, n=18, 43%, p=0.031)
and located more often in oropharynx (n=33, 79%, p=0.007). Furthermore, non-smokers had
more EMT- tumors (n=11, 26%, p=0.034). It was possible to detect either snai1 or twist
stromal immunoreactivity in thirty eight (35%) patients. The tumors were larger according
to the number of positive transcription factors (p=0.034) (Table 8).
Table 8. Expression of twist and/or snai1 in tumor stroma in different T categories
Stromal expression of twist  and/or snai1
T classification EMT-
n (%)
twist or snai1 +
n (%)
EMT+
n (%)
p
T1 and T2 27 (25) 15 (14) 11 (10) 0.034
T3 and T4 15 (14) 23 (21) 18 (16)
5.2.7 Co-expression of other transcription factors
There was a distinct association between tumor epithelial and especially stromal staining of
sip1,  slug  and  zeb1.  The  co-expression  of  all  five  EMT-RTFs  is  detailed  in  Table  9.  We
stratified a subgroup of tumors (n=17, 16%) where snai1, twist and sip1 all co-expressed in
tumor  epithelial  cell  nuclei.  In  this  subgroup,  all  tumors  were  at  least  stage  III  (p=0.003).
The tumors located more commonly in hypopharynx (n=11, 65%, p=0.009), were larger (T3-
4, n=13, 76%, p=0.02), and had more lymph node metastases (N1-3 n=11, 65%, p=0.04).
Almost all of these tumors were well or moderately differentiated (n=15, 88%, p=0.04).
There were 19 samples where none of the three transcription factors were expressed in the
tumor epithelium. However no significant correlation with any of the clinicopathological
variables was seen in this subgroup. In 17 samples (15.6%) snai1, twist and sip1 were all
expressed in tumor stroma. In this subgroup, only two patients recovered whereas the
other 15 either relapsed or did not attain remission (p=0.05). In 31 samples, none of those
transcription factors were expressed in tumor stroma (28.4%). In that latter group, most of
the tumors were small (T1-2) at presentation (n=21, 68%, p=0.007).
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Table 9a. Correlations of positive tumor epithelial cell nuclear stainings
sip1
n=44
slug
n=57
zeb1
n=34
twist
n=38
sip1  n=44
slug  n=57 SpCC   0.22 *
p 0.02
zeb1  n=34 SpCC   -0.10   -0.04
p 0.30    0.71
twist  n=38 SpCC 0.17 0.00 0. 25 *
p 0.08 0.99 0.01
snai1  n=75 SpCC   0.21 * 0.36 **   0.22 * 0.08
p 0.03 0.00 0.03 0.42
Sp.CC Spearman’s correlation coefficient
*. Correlation is significant at the 0.05 level.
**. Correlation is significant at the 0.01 level.
 Table 9b. Correlations of positive tumor stromal cell nuclear stainings
sip1
n=38
slug
n=60
zeb1
n=38
twist
n=44
sip1   n=38
slug  n=60 SpCC 0.58 **
p 0.00
zeb1  n=38 SpCC 0.37 ** 0.50 **
p 0.00 0.00
twist  n=44 SpCC 0.50 ** 0.40 ** 0.64 **
p 0.00 0.00    0.00
snai1  n=49 SpCC 0.34 ** 0.07 0.28 ** 0.40 **
p 0.00 0.49   0.01 0.00
Sp.CC= Spearman’s correlation coefficient
**. Correlation is significant at the 0.01 level.
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5.3 SURVIVAL ANALYSES
5.3.1 Clinicopathological factors
A  summary  of  univariate  analysis  of  clinicopathological  factors  and  DSS  is  presented  in
table  10.  The  most  important  prognostic  factors  in  this  analysis  were  tumor  size  (T  class)
and stage together with the general condition of the patient. Hypopharyngeal carcinomas
had a significantly poorer prognosis than oropharyngeal carcinomas and distant metastases
naturally deteriorated the prognosis. Age, gender, consumption of tobacco or alcohol, or
length of time period between first symptoms and diagnosis or histological grading did not
have any effect on the prognosis.
Table 10. Kaplan-Meier univariate analysis of associations between various clinicopathological
factors and DSS (Significant values marked bold)
variable (n) number of deaths in PSCC,
5-years follow-up
p-value
gender      male (82) 46 (56%)
female (27) 18 (67%) 0.515
age           <64,6 (60) 34 (57%)
64,6 (49) 30 (61%) 0,423
no tobacco smoking (19) 9 (47%)
tobacco smoking (67) 40 (60%) 0.226
no alcohol consumption (14) 8 (57%)
alcohol consumption (53) 28 (53%) 0.703
KPS score < 70 (37) 29 (78%)
 70 (72) 35 (49%) 0.000
Duration of symptoms before dg. <5.3 months (78) 46 (59%)
5.3 months (31) 18 (58%) 0.605
BMI <20 (13) 9 (69%)
         20-25 (50) 32 (64%)
       >25 (41) 21 (51%) 0.054
T class 1 (13) 4 (31%)
           2 (40) 15 (38%)
           3 (21) 13 (62%)
           4 (35) 32 (91%) 0.000
N class 0 (63) 32 (51%)
           1-3 (46) 32 (70%) 0.059
M class 0 (105) 60 (57%)
           1 (4) 4 (100%) 0.030
Stage  I (9) 2 (22%)
          II (25) 6 (24%)
          III (21) 11 (52%)
          IV (54) 45 (83%) 0.000
Histological grade 1 (26) 15 (58%)
                           2 (48) 28 (58%)
                           3 (35) 21 (60%) 0.954
Primary site oropharynx (69) 35 (51%)
                  hypopharynx (40) 29 (73%) 0.035
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5.3.2 EMT-related transcription factors
In Kaplan-Meier univariate analysis, positive snai1 immunoreactivity in endothelial cell
nuclei  strongly  predicted  poor  five-year  DSS  (p  =  0.009).  Additionally,  there  was  a  trend
noted between stromal nuclear snai1 expression and poor DSS (p = 0.067).  In contrast,
epithelial nuclear expression of snai1 was not related to prognosis. Neither epithelial nor
stromal cell nuclear expression of twist alone associated with DSS or OS in the univariate
analysis. Instead, the EMT- group experienced a statistically significantly better 5-year
survival as compared to patients who had positive twist or snai1 stromal expression (DSS
p=0.037; OS p=0.014). The 5-year prognosis tended to worsen as the number of positive
transcription factors detected increased (DSS p=0.113; OS p=0.043).
Tumor epithelial cell nuclear sip1 immunoreactivity correlated significantly with five-
year DSS and OS, the estimated disease specific survival time being 37 months for patients
with sip1 negative and 26 months for sip1 positive tumors (DSS p=0.012, OS p=0.003).
Similarly, stromal cell nuclear sip1 positivity also correlated statistically significantly with
DSS and OS (p=0.018 and p=0.003, respectively). No such correlation with survival was
found for slug or zeb1 immunostainings (DSS, p=0.16 and p=0.44, respectively).
Cox  proportional  hazards  model  included  age,  KPS  score,  T-class,  N-class,
histolopathological grade and the EMT-RTFs as variables.  Positive epithelial cell nuclear
staining of  sip1 was an independent  prognostic  factor  for  DSS and OS together  with  KPS
score and T-class (DSS p=0.046, p=0.001, p<0.001 and OS p=0.023, p<0.001, p<0.001,
respectively)(Fig.12),(Table12).
Months
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sip1 negative
n=64
p=0.046
sip1 positive
n=44
Figure 12.  Cox proportional hazards model of 5-year survival analysis of pharyngeal squamous
cell carcinoma. Sip1 expression in tumor epithelial cell nuclei predicts poorer disease specific
survival (p=0.046).
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In the group where snai1, twist and sip1 were all co-expressed in the epithelial cell nuclei,
both DSS and OS were very poor (p<0.001) (Fig. 13). None of these patients was alive after 5
years and the mean survival time was a mere 12 months. The result remained similar also
in Cox proportional hazards model i.e. the epithelial co-expression of these three
transcription factors was an independent prognostic factor for poorer DSS and OS (p=0.002
and p<0.000) in PSCC, together with KPS score and T-class (p=0.002 and p<0.001,
respectively). The DSS and OS were significantly better if no expressions of snai1, twist or
sip1 were detected in tumor stroma (p=0.05, p=0.02 respectively) (Fig. 14). However, this
was not an independent prognostic factor in the Cox proportional hazards model. A
summary of the univariate analysis of all EMT-RTF expressions and co-expression in
association with DSS is presented in table 11. All statistically significant predictors of DSS
in Cox proportional hazards model are shown in table 12.
positive expression
n=17
no expression
n=90
p<0.001
Months
Figure 13.  Kaplan-Meier  univariate  5-year  survival  analysis  of  pharyngeal  squamous  cell
carcinoma. In the group where snai1, twist and sip1 are all expressed in tumor epithelial nuclei
DSS is significantly poorer (p<0.001).
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no expression
n=30
positive expression
n=79
p=0.006
Months
Figure 14.  Kaplan-Meier  univariate  5-year  survival  analysis  of  pharyngeal  squamous  cell
carcinoma. When there is no expression of snai1, twist or sip1 in tumor stroma, the DSS is
significantly better (p=0.006).
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Table 11. Kaplan-Meier univariate analysis of association of EMT-marker nuclear expressions
and DSS (Significant values marked bold)
EMT-marker/group of markers Number of deaths in PSCC, 5-
years follow-up
p-value
snai1 tumor epithelium pos. (75) 44 (59%)
                                   neg. (34) 20 (59%) 0.387
snai1 tumor stroma  pos. (49) 32 (65%)
                               neg. (57) 30 (53%) 0.067
snai1 endothelium pos. (54) 38 (70%)
                            neg. (55) 26 (47%) 0.009
twist tumor endothelium pos. (38) 24 (63%)
                                     neg. (69) 40 (58%) 0.265
twist tumor stroma pos. (44) 28 (63%)
                             neg. (65) 36 (55%) 0.253
sip1 tumor epithelium pos. (44) 31 (70%)
                                 neg. (64) 33 (52%) 0.012
sip1 tumor stroma pos. (38) 27 (71%)
                            neg. (65) 35 (54%) 0.018
sip1 endothelium pos. (63) 37 (59%)
                          neg. (46) 27 (59%) 0.833
sip1 cytoplasm pos. (44) 30 (68%)
                       neg. (64) 34 (53%) 0.181
slug tumor epithelium pos. (57) 36 (63%)
                                  neg. (51) 28 (55%) 0.158
slug tumor stroma pos. (60) 35 (58%)
                            neg. (46) 27 (59%) 0.618
slug endothelium pos. (54) 35 (65%)
                           neg. (55) 29 (53%) 0.240
slug cytoplasm pos. (55) 35 (63%)
                       neg. (54) 29 (54%) 0.291
zeb1 tumor epithelium pos. (34) 22 (65%)
                                  neg. (75) 42 (56%) 0.338
zeb1 tumor stroma pos. (38) 23 (61%)
                              neg. (71) 41 (58%) 0.496
zeb1 endothelium pos. (61) 37 (61%)
                           neg. (48) 27 (56%) 0.942
snai1+twist stroma pos. (EMT+) (29) 18 (62%) 0.314
snai1+twist stroma neg. (EMT-) (42) 20 (48%) 0.037
snai1+twist+sip1 epit.pos. (17) 14 (82%) 0.000
snai1+twist+sip1 epit. neg.(19) 10 (52%) 0.368
snai1+twist+sip1 str. pos. (17) 12 (71%) 0.141
snai1+twist+sip1 str neg. (31) 15 (48%) 0.049
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Table 12. Statistically significant predictors of DSS in Cox proportional hazards model
variable p-value
T-class (T1-2/T3-4) <0.001
KPS score (70/<70) 0.001
sip1 epithelial nuclear expression (neg./pos.) 0.045
snai1, twist and sip1 epithelial nuclear co-expression (neg./pos.) 0.002
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6  Discussion
6.1 THE STUDY DESIGN, COHORT AND CLINICAL DATA
6.1.1 Cohort and methods
The  original  population  of  138  cases  consisted  of  all  the  oro-  and  hypopharyngeal  SCC
patients diagnosed in the Eastern Finland area during the study period. Sufficient tissue
material for microarrays and immunohistochemical stainings was available from 110 to 108
samples.  Two  array  spots  had  diminished  to  too  small  an  area  to  allow  a  reliable
interpretation of the stainings. The utilization of array spots instead of the whole tumor
preparate diminishes the investigated area and carries a possible risk for mis-interpretation.
The spots were, however, meticulously selected by an experienced pathologist so that they
would contain a representative area of the tumor invasive front and stromal tissue. Array
spots have been widely used in several previous immunohistochemical
studies.(39,193,209,210) In a study of thyroid carcinomas, the immunohistochemical
stainings  were  conducted  for  both  whole  sections  and  array  spots  and  the  results  were
reported to be closely matched.(211) The use of immunohistochemistry as the only study
method has to be considered as a deficiency of this thesis. However, immunohistochemistry
is a widely used and well documented method exploited in many clinical trials with
survival analyses.(27,30,34-36,38)
     HNC is a very diverse set of malignomas originating from various anatomical sites. The
classification of the sites between studies has varied extensively complicating the
comparison of the obtained results. The decision to exclude nasopharyngeal carcinoma
from this study was made in an attempt to homogenize the material since nasopharyngeal
carcinoma differs from oro- and hypopharyngeal carcinomas remarkably in its etiology,
histopathology, clinical features and prognosis.(55) However, oro- and hypopharyngeal
SCCs share the same risk factors, histopathology and to some extent also clinical features
and treatment protocols. Although hypopharyngeal tumors had a worse prognosis as
compared to their oropharyngeal counterparts, the site was not an independent prognostic
factor suggesting that combination of these subgroups does not distort the survival data. In
several earlier studies,  all  the HNCs or HNSCCs originating from various sites have been
combined into the same material.(151,170,178,212-214)
     The study period is very long with the earliest samples being over 30 years old. PSCC is
however a rather rare disease and the study period has to be prolonged to gather a material
large enough into permit reliable statistical analyses. In order to avoid the effect on
different storage times on histological stainings, the material was previously
chronologically divided to ten subgroups and the independence of histological variables
was  compared  with  Fisher’s  exact  test.(215)  There  was  no  statistical  difference  between
those subgroups.(215) Moreover, all the immunohistochemical stainings succeeded
technically well with consistent staining results and they were interpreted without any time
delay. The diagnostic criteria, classification and treatment protocols have remained very
stable throughout the study period.
6.1.2 Clinical variables and prognostic factors
In the present material, a typical patient at the time of PSCC diagnosis was an elderly man
with advanced disease. That description is in line with previous studies about pharyngeal
carcinoma.(51,55,90,216) Moreover, the symptom spectrum in this study was rather similar
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in comparison with the literature.(55,216,217) The delay from symptoms to diagnosis was
three  months,  slightly  shorter  that  that  described  in  a  Spanish  material  from  the  same
decades  (4,5  months).(55)  This  might  suggest  that  our  health  care  system  is  rather
comprehensive. Nonetheless, the delay from primary symptoms to diagnosis is still longer
in  PSCC  than  in  many  other  cancers  due  to  its  nonspecific  symptoms  and  also  due  to
lifestyle of the typical patient. In the present cohort, 62% of the patients reported that they
were current or previous smokers and 49% declared modest to profound alcohol
consumption. Neither of these parametres correlated with survival or other
clinicopathological variables, although benzo[a]pyrene in cigarettes has shown to induce
EMT and promote disease progression in lung cancer patients.(218) However, information
of smoking and alcohol consumption in the present study was gathered from the medical
records without any specific confirmation. Moreover, the information of smoking was
missing in 23 cases and that on alcohol consumption was not known in 42 cases. Therefore,
that information should be viewed with caution. The number of nodal metastases was
lower  in  the  present  material  (43%)  than  in  previous  studies  on  oropharyngeal  and
pharyngeal SSCs (70% and 60%, respectively).(55,90)
     In the current material, 100 (91%) of the patients received radiotherapy either as a
primary  treatment  (63%)  or  as  an  adjuvant  therapy  (28%).  Primary  surgery  had  been
performed  in  36  cases  (33%)  and  neck  dissection  in  17%  of  the  cases.  In  a  Finnish
nationwide study of oropharyngeal carcinoma conducted during 1995-1999, primary
radiotherapy was given to 14% and combined radiotherapy with surgery to 76% of the
patients. In that study, neck dissection was performed in 70% cases.(90) In hypopharyngeal
carcinomas, surgery is rarely the primary treatment, which explains the differences
between the  results  in  comparison to  the  present  study.  DSS survival  was  22.4  months  in
the current material, 40.7 for oropharyngeal and 17.9 for hypopharyngeal carcinoma, with
the median OS being 20.9  months.  These  data  are  very well  in  line  with  previous  studies
with Finnish population.(51,90)With respect to the clinical factors studied, T-class or stage
as  well  as  KPS  score  remained  independent  prognostic  factors  in  multivariate  analysis
which is fully in agreement with previous studies.(7,57,89-91) KPS score which reflects the
patient’s  general  condition  was  rather  low  in  the  present  material  since  in  34%  of  the
patients  the  score  was   less  than  70.  Pharyngeal  carcinoma  causes  pharyngeal  pain  and
dysphagia affecting nutritional intake and thus commonly resulting in deterioration of a
general condition of the patient.  The low BMI values, less than 20, revealed a poorer DSS
also in the present material. In addition, many patients are alcoholics with a poor life style
and possibly with other untreated medical conditions.
     Interestingly histological grade had no association with survival in the current material.
That observation has been made also in several other HNC materials.(34,38,57,89,179,219)
Traditionally tumor differentiation is often believed to describe disease aggressiveness and
prognosis, as also in PSCC. However, according to the present results, it is not very suitable
for that purpose. Tumor size has a much stronger effect on the patient’s survival and it  is
not  dependent  on  cell  differentiation.  Furthermore,  sip1,  found  to  be  an  independent
prognostic factor in the present study, is usually expressed in well differentiated tumors.
This prposal is still not definitive but certainly needs and deserves to be further
investigated.
6.1.3 HPV
In the 1980’s a Finnish research team noted that 40% of oral SCCs in their study contained
similarities with HPV-associated lesions.(220) This discovery initiated a new way of
thinking: there are two different types of HNCs and especially oropharyngeal carcinomas
taking notice of risk factors and clinical features. Patients with HPV-positive tumors are
often non-smokers and non–drinkers with a smaller tumor size and better survival.  HPV-
positive tumors are also more sensitive to radiation and chemotherapy than HPV negative
tumors.(7,8,91) P16 is an established biomarker for the function of the HPV E7 oncoprotein
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and it  is  widely  used for  detection of  HPV positive  tumors.(9,91)  The p16 status  was also
evaluated in the present oro- and hypopharyngeal SCC material. In the whole material, p16
positivity was detected in only 19 (18%) of the whole study group (n=107) and in ten (25%)
samples of oropharyngeal orgin. This incidence is slightly less than that reported in earlier
publications.(7,91) The current material is rather old and the prevalence of HPV infection
may have risen during the recent years which, at least partly, explains the difference.(8) The
p16 positivity correlated with small tumor size (T1-2), poor differentiation grade (Gr 3) and
lymph  nodal  metastases  such  as  in  previous  studies.(91,92)  There  was,  however,  no
correlation with expression of EMT-RTFs and p16. In Kaplan-Meier univariate analysis, p16
negative patients had lower DSS and OS (p=0.012 and p=0.002, repectively) but it was not
an independent prognostic factor in multivariate analysis unlike sip1 epithelial expression,
T-class and KPS score (data not shown). Thus, according to the current study, sip1 seems to
be a more important prognostic marker for survival than p16 in PSCC.
6.2 EMT AND TRANSCRIPTION FACTORS
6.2.1 EMT and tumor-stroma interference
In addition to normal embryogenesis, EMT occurs in many pathological situations such as
wound healing, fibrosis and acquisition of the invasive phenotype in epithelial tumors.(13)
Tumor cells undergoing EMT lose their epithelial feathures and gain motile and invasive
characteristics. Successful induction of EMT in tumor progression seems to be dictated by
three factors: the differentiation program inherited from the normal cell origin, genetic and
epigenetic changes accumulated during tumor progression and the signals that tumor cell
is receiving from the nearby activated stroma.(221) Initiation of signal transduction
cascades can be manifest in disparate outcomes in different cell and tumor types.
The  EMT  process  has  assumed  to  be  fundamental  in  tumor  progression  and
metastasizing. There has been, however, skepticism regarding the pathological relevance of
EMT  on  grounds  of  its  infrequent  occurrence  in  several  tumors  and  also  the  lack  of
mesenchymal markers in metastases.(110,222) It has also been claimed that the complete
transition to mesenchymal phenotype is not required for invasion and metastases but
tumor cells can invade by collective migration even while still displaying an epithelial
phenotype.(110) It is difficult to obtain in vivo proof of existence and importance of EMT in
cancer  progression  but,  nevertheless,  there  is  accumulating  evidence  to  support  its
significant role in the immensely complex context of cancer development and
progression.(13,15,96-98,101,113)
Equally  controversial  is  also  the  existence  and  significance  of  CSC  in  tumorigenesis.  It
has been postulated that there is a subgroup of cancer cells which possesses the ability to
self-renew and to differentiate into all cell types. (131,223) They remain in a quiescent state
and  are  endowed  with  enhanced  DNA  repair  mechanisms  thus  becoming  resistant  to
chemo- and radiation therapies. Therefore they play an important role in cancer relapses
and metastases.(204,205) EMT can trigger reversion to a CSC-like phenotype through TGF-
 and WNT pathways, thus contributing tumor progression.(131)
EMT is a reversible process which is balanced between complicated regulatory networks
and microenvironmental signals.(113) MET is prerequisite for disseminated tumor cells to
proliferate  and  form  distant  metastases.  When  the  disseminated  cells  no  longer  receive
signals  from the  primary tumor surroundings,  the  cellular  phenotype reverses  back to  its
epithelial state, thus resulting the epithelial phenotype of metastases.(96,97,101,117,171)
Due to the reversible nature of EMT process, it is unlikely that EMT-inducing transcription
factors  are  permanently  altered  at  the  genomic  level  but  ,instead,  are  variably  expressed
while being controlled at both the transcriptional and translational levels.(171) Epigenetic
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regulation encompasses three types of changes, DNA methylation, histone modifications
and  miRNAs,  each  of  which  has  been  shown  to  play  an  important  role  in  controlling
EMT.(114) These epigenetic modifications are reversible,  contributing to plasticity in EMT-
MET  –processes.(113)   However,  there  are  also  somatic,  irreversible  mutations  in  tumor
growth regulating genes which can act in conjunction with epigenetic regulation.
The EMT markers are often present in tumor stroma close to the invasive front,  as was
also seen in the present study. A proportion of stromal cells might represent transformed
tumor  cells  which  had  gone  through  EMT.  Furthermore,  in  a  response  to  growth  factors,
transcription factors might stimulate the conversion of stromal fibroblasts into more motile
myofibroblasts.(125) There are also non-neoplastic activated fibroblastic cells in tumor
stroma which may express transcription factors due to their interactions with epithelial
cancer cells. These stromal cells might also express transcription factors and cannot be
distinguished by immunohistochemistry alone from EMT transformed stromal cells..
6.2.2 Snai1
There  are  a  large  number  of  studies  with  snai1  in  diverse  set  of  carcinomas  presenting
occasionally contradictory expression data.(112,224) That could be partly due to the
undefined specificity of commercial anti-snai1 antibodies. The anti-snai1 antibody used in
the current study is one of the recently developed non-commercial monoclonal anti-snail1
antibodies that have been well-characterised and show evident nuclear
staining.(207,208,225) There is also a considerable variation between methods used in each
study and also in classifying of positive staining results. All that in addition to sometimes
inaccurate discrimination between nuclear and cytoplasmic staining makes the comparison
of the results between published studies very challenging. In the present study, cytoplasmic
staining was seen in only 4 samples. The significance of cytoplasmic reactivity is, however,
unclear and because snai1 activity is controlled by its subcellular location, only nuclear
snai1 is believed to be active and stable.(145)
Immunoreactivity of snai1 has been detected previously in epithelial cancer cells in
HNSCC (28,37,226) as it has also in several other cancer types. (22,29,136,148,149,207,225)
As  shown  here,  snai1  expression  is  more  abundant  in  stromal  cells,  in  agreement  with
reports from various other malignant tumors.(29,37,136,207,226,227) The expression of
snai1  in  epithelial  cells  is  thought  to  take  place  already  in  the  early  phases  of  tumor
development. In a previous study by our group, the snai1 protein expression was examined
during  ovarian  tumor  development  in  the  transition  from  precursor  lesions  into
carcinomas.(136) In benign tumors, no epithelial or stromal staining was observed in
contrast to the situation in borderline tumors and especially in carcinomas, supporting a
role for snai1 in early tumorigenesis. There is increasing evidence revealing that early and
late  state  EMT  may  have  different  molecular  profiles.  Subcellular  localization  may  be  an
indicator for early EMT whereas elevated total levels of markers could be evidence of late
EMT.(228)
According to many reports investigating several human carcinomas, epithelial nuclear
expression of snai1 protein is not associatecd with survival, (29,136,149,225) except in a
recent study, where epithelial snai1 overexpression was claimed to significantly decrease
the  survival  of  patients  with  lung  adenocarcinoma  but  not  in  lung  SCC.(22)  However,  in
colorectal carcinomas, snai1 expression in tumor stroma associated with lower DSS and the
presence of distant metastases.(29) In the present study, those patients with stromal snai1
expression in their tumors displayed a trend towards poorer survival. These findings
indicate  that  snai1  is  expressed  in  the  stroma  of  locally  advanced  PSCC  tumors  where  it
may modify the tumor microenvironment facilitating further cancer progression. Snai1 is
present in activated mesenchymal cells pointing to its relevance in the communication
between  the  tumor  and  the  stroma.(207)  Mesenchymal  expression  of  snai1  has  been
suggested to stimulate invasion and angiogenesis in tumor.(229) Snai1 expression in
stromal cells in the vicinity of tumor might also partly represent epithelial tumor cells that
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have undergone EMT.(207) Furthermore, the interaction between epithelial and stromal
cells during tumorigenesis may stimulate stromal cells to express snail1.(37)
In the present study, snai1 expression was detected in a subset of endothelial cells and it
associated statistically significantly with poor DSS in these PSCC patients.  This is the first
study to indicate that endothelial cell staining is related to poor survival in PSCC, although
it was not an independent prognostic factor in the multivariate analysis. Snai1 expression in
endothelial cells may be evidence that the protein takes part in the endothelial-
mesenchymal  transition  (EndMT)  which  has  been  shown  to  be  an  important  source  of
cancer-associated fibroblasts.(200) As reported by Kokudo et al.,snai1 mediates the actions
of endogenous TGF signals and these have been shown to induce EndMT.(230) EndMT
has been suggested to play a role in activation of angiogenesis thus promoting tumor
growth.(201)
In these samples, snai1 expression was occasionally detected adjacent to necrotic and
inflammatory areas. Snai1 expression and function may be triggered by hypoxia.(112,231)
This  kind  of  activation  of  snai1  may  take  place  also  in  large,  poorly  vascularised  PSCC
tumors and it may possibly explain the more intense snai1 expression in hypopharyngeal
tumors,  which  are  usually  larger  at  the  time  of  diagnosis.  Staining  in  or  close  to
necroinflammatory areas could reflect the anti-apoptotic functions of snai1.(119)
Proinflammatory mediators like interleukin 1 are shown to upregulate snai1 and this way
inflammation is supposed to promote EMT and tumor progression.(232) Inflammation
induced factors also possibly stabilizes the snai1 protein.(147)
6.2.3 Twist
Twist has several properties that facilitate tumor progression including the triggering of
EMT, inhibition of apoptosis and the enhancement of angiogenesis.(172,233) Twist has also
been shown to induce EMT through chromatin remodeling.(173) Twist overexpression
correlates with E-cadherin downregulation in HNSCC cell line.(173) However, in a study of
nasopharyngeal carcinoma, snai1 expression was associated with repressed E-cadherin
expression while twist expression had no influence on the expression of E-cadherin.(234)
Thus, EMT regulators show varied expression profiles and distinct roles in different kinds
of carcinomas. In the present study, the nuclear staining intensity of twist was detected in
the stromal component more often than in epithelial cancer cells. The same phenomenon
has been observed with snai1 in several carcinomas.(29,37,136,207,226,227) There was a
trend towards a more pronounced twist staining intensity in larger and more advanced
stage  tumors.  In  a  recent  study  in  patients  with  oral  SCC,  twist  was  expressed  in
carcinomas but not in benign tissue samples.(179) Furthermore in ovarian tumors twist
expression increased stepwise in normal, borderline and malignant tumors.(135)
Consequently,  the expression of twist seems to intensify with tumor progression.
Stromal expression of twist was more frequent in hypopharyngeal than in oropharyngeal
tumors. It remains unclear whether this is due to the more advanced disease stage at the
time of diagnosis with its possibly more hypoxic conditions, or if it represents a true feature
of the hypopharyngeal tumors with a very poor overall prognosis. Interestingly, the
patients with stromal twist and snai1 negative tumors were more often non-smokers. In
bladder cancer, most of the patients with positive twist expression were current
smokers.(235) This agrees with the previous hypothesis that smoking could modulate the
expression of EMT markers. The aromatic hydrocarbon B[a]P which is present in tobacco
smoke  has  been  shown  to  cause  EMT-like,  partly  irreversible,  dynamic  changes  in  gene
expression including twist up-regulation. (218)
To date, there are only a few other studies investigating the association between twist
expression  and  clinicopathological  features  in  HNSCC.  In  the  studies  of  Fan  and
Gasparotto, twist expression showed no association with either prognosis or
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clinicopathological variables.(179,214) In a rather small cohort of various head and neck
squamous cell carcinomas (n=50), nuclear and cytoplasmic staining of twist correlated with
histologic differentiation grade, advanced stage and large neck lymph node
metastases.(178) The comparison of these data with the present study has to be conducted
with care.  Since transcription factors are considered to be active only when located in the
cell nuclei (145), cytoplasmic staining was not included into the present evaluation. In this
study, twist expression alone did not associate with survival. There is some evidence of
positive staining of twist and poor survival in HNSCC and similarily in oesophageal
SCC.(31,170) In addition, twist expression in the epithelial compartment of breast
carcinoma was associated with poor survival.(236) Evidently, tumors from different sites
and with different histology vary in their twist expression profile. There is also variations in
the classification strategies used in different publications. The cut-off points between
positive and negative values diverge and in some studies also staining intensity has been
included  in  the  evaluation.  This  makes  the  direct  comparison  of  the  results  rather
challenging.
According to previous studies, twist has been postulated to be responsible for regulation
of metastasis development. In breast tumor cell lines, twist has been shown to promote the
early steps of tumor metastasis, where tumor cells gain access to the circulation with no
apparent benefit to the growth of the primary tumor.(20) Twist expression also correlates
with distant metastases, for example in esophageal SCC.(237)  In the present study, patients
with epithelial cell nuclear expression of twist tended to have more neck lymph node
metastases although the difference was not statistically significant. The metastatic event is a
complex process with many diverse phases and there are certainly also several other factors
regulating it.
There are no published data about the half-life of twist or on its stability within the cell
nucleus but snai1 is known to be highly unstable.(145) As is typical for transcription factors
it is probable that twist is expressed in tumor cells for only a very short time period which
might explain why only one third of the epithelial cancer cells expressed twist in their cell
nucleus.  Some  of  the  stromal  cells  may  represent  transformed  epithelial  cancer  cells
undergoing  EMT.(96)  That  could  be  one  explanation  for  the  stromal  staining  of  twist
observed also in the present material.
6.2.4 Sip1, slug and zeb1
E-cadherin downregulation has been considered as a principal landmark of EMT. Sip1
binds to the promoter area of E-cadherin, inducing its downregulation.(19) However, the
association  between  E-cadherin  and  sip1  is  somewhat  ambiguous.  In  OSCC,  there  is  no
significant inverse correlation between these factors.(194) This raises the possibility that
sip1 has functions other than downregulation of E-cadherin. Sip1 expression causes also
downregulation of other major constituents of tight junctions, adherens junctions,
desmosomes  and  gap  junctions  at  the  transcriptional  level.(180)  In  squamous  cell
carcinoma, the precence of sip1 also protects the cells from DNA-damage-induced
apoptosis.(27) Different levels of regulation influence the spatio-temporal expression of sip1
protein  which  may  point  to  an  ability  for  this  protein  to  play  diverse  roles  in  different
contexts.(18) There are several studies investigating sip1’s role in the development of
multiple cancers.(27,195,238) However, as far as is known no previous studies have
examined the role of sip1 in PSCC.
Sip1 expression in human tissues and tumors varies considerably and both nuclear and
cytoplasmic expressions have been described in various sites.(27) In the present study, sip1
was  expressed  abundantly  in  both  tumor  epithelial  cell  nuclei  and  cytoplasm.  There  was
also  profuse  stromal  and  endothelial  staining  in  these  tissue  samples.  Sip1  has  been
previously detected in tumor cell nuclei, stromal fibroblasts or cytoplasm in 28% of oral
squamous cell  carcinoma samples (34) and in cell  nuclei of 40% of head and neck spindle
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cell carcinoma samples.(239) Thus, the present results are in line with these previous
findings.  Snai1  has  shown  to  be  very  unstable  and  thus  only  nuclear  protein  is  again
considered to be active.(145) The half life of sip1 has not been reported. Cytoplasmic
expression of sip1 was as abundant as nuclear staining but the expression did not correlate
with tumor progression or survival. Therefore, these results support the view that only
nuclear expression of sip1 is significant.
This is the first study to demonstrate, that sip1 alone and together with other
transcription factors can enhance tumor progression in PSCC. Epithelial expression of sip1
in the nuclei of carcinoma cells was associated with advanced stage and higher lymph node
status.  Sip1  expression  also  had  a  major  impact  on  the  patient’s  DSS.  This  may  be  partly
caused  by  advanced  stage  and  lymph  node  metastases  but  epithelial  expression  of  sip1
remained an independent prognostic factor also in the Cox proportional hazards model,
together with KPS and T-class. A similar association between increased sip1 expression and
decreased  survival  has  been  earlier  shown  in  oral  SCC.(34)  Furthermore,  sip1  has  a
negative effect on survival in urothelial and non-small cell lung cancer.(27,195) This
implicates sip1 as a potential marker of aggressiveness of such carcinomas. In the present
material, sip1 expression was increased in less-differentiated carcinomas, a phenomenon
also  found  in  oral  SCC  by  Maeda  et  al.(34)  Histological  grading  alone  had  no  effect  on
survival  in  neither  of  the  analyses.  Thus,  it  is  possible  that  sip1  directly  enhances  tumor
progression and metastases independently of cellular differentiation.
In the present study, the stromal nuclear expression of sip1 correlated with elevated risk
of tumor relapse. In oral SCC, sip1 overexpression predicted a delayed appearance ofneck
metastases. (194) It  has  been  proposed  that  snai1  reflects  early  EMT  alterations  and  other
transcription factors,  like  sip1,  could be  responsible  for  maintenance of  the  migratory cell
behavior.(112) Accordingly, the immunostained stromal cells might, at least partially,
represent the transformed tumor cells that have undergone EMT. These motile cells would
thus be capable of invading adjacent tissues and vessels to promote metastases and
recurrences.  On  the  other  hand,  non-neoplastic  stromal  fibroblasts  may  express
transcription factors by interacting with adjacent epithelial cancer cells. The signification of
stromal  tissue  in  tumor  progression  has  been  studied  and  emphasized  in  recent
years.(109,124,127,130,240) In this way, these modified stromal fibroblasts may be not only
enablers, but even potential inducers of malignancies.
Sip1 and slug expression was more frequent in hypopharyngeal than in oropharyngeal
tumors as also established with twist. It still remains unclear whether this is due to the
more advanced disease stage at the time of diagnosis or whether it represents a true feature
of  the  hypopharyngeal  tumors.  There  are  different  expression  patterns  of  EMT  related
transcription factors in carcinomas of various origins.(157,193) On the other hand,
transcription factors facilitate tumor growth by triggering EMT, inhibiting apoptosis and
enhancing angiogenesis and thus their expression often reflects advanced
tumors.(19,27,233)
Even though slug has been associated with cancer progression in colorectal carcinoma
and esophageal SCC,(30,165) in the present study, the expression of slug did not correlate
with prognosis. Furthermore in another study investigating oral SCC, slug expression
failed to display any association with clinicopathological variables and survival.(38) This
again implies that there are different roles of EMT related transcription factors in distinct
tumors.  In  a  very  recent  study  with  HNC  cell  lines,  there  were  poor  survival  rates  when
both  zeb1  and  sip1  were  highly  expressed.(213)  As  far  as  is  known  there  are  no  other
previous  studies  about  zeb1 in  head and neck carcinoma.  However,  in  the  current  study,
there was no correlation between zeb1 expression and clinicopathological variables or
survival.
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6.2.5 Co-expression of EMT-RTFs
The  present  study  revealed  a  moderate  co-expression  of  all  the  transcription  factors  in
tumor epithelium and the  expression of  snai1  and slug correlated clearly,  possibly  due to
their common origins and structure. The stromal expressions of all five transcription factors
were strongly associated to each other. A strong correlation between the EMT-RTFs has
been shown also in ovarian carcinoma.(135) In order to analyze previously published data
about the correlations of gene expressions of the EMT related transcription factors the
GeneSapiens database was utilized (http://www.gene sapiens.org). It was possible to detect
34 analyses in head and neck carcinoma revealing a significant positive correlation between
the expression levels of sip1 and slug (p=0.047), zeb1 and twist (p<0.001) and a clear trend
suggestive of a correlation between snai1 and sip1 (p=0.056). No correlation was seen
between the transcription factors in normal oral or pharyngeal tissue samples implying that
the cooperation between the transcription factors takes place particularly in malignant
tissue,  as  also  reported  by  Kilpinen  et  al.(241)  During  embryogenesis,  many  EMT  related
transcription factors are often activated simultaneously.(198) However, in distinct tumors
these transcription factors also seem to work separately. There is also a certain hierarchy
between the factors, for example, twist needs direct induction from slug to induce
EMT.(198)  In  the  diffuse  type  of  gastric  carcinomas,  slug,  snai1  and  sip1  seem  to
complement each another.(242)
In the present study, the tumors that did not express either twist or snai1 in stroma were
smaller, of lower stage and were more often situated in the oropharynx. Those tumors also
had a significantly better 5-year DSS. On the contrary, positive snai1 and twist stromal
expression  associated  with  larger  tumor  size  and  more  advanced  stage.  Other  previous
studies with twist and snai1 also support the hypothesis that these two transcription factors
act in collaboration to promote EMT and tumor progression, even though they are
regulated independently.(35,36,169) In the present material, tumors which expressed
simultaneously three transcription factors, snai1, twist and sip1, in the epithelial nuclei
were larger and more advanced. The prognosis of the patients found with these tumors was
dismal  the  mean  DSS  being  only  12  months.  The  result  was  significant  also  in  the
multivariate analysis together with T-class and KPS.  These results reveal a remarkable
propensity of the transcription factors to co-operate and intensify one another’s function in
the present PSCC cohort. It is evident that elevated nuclear expression of transcription
factors is indicative of ongoing EMT. There is growing evidence that snai1 could be an early
marker  of  EMT  while  other  EMT-RTFs  may  be  responsible  for  the  maintenance  of
tumorigenic properties.(112) TGF is a key molecule that might promote the interplay
between the transcription factors during EMT.(112) However, hypoxia is also thought to be
a significant factor co-ordinating the interplay which possibly relates to the observation of
accumulation of EMT-RTFs in association with tumor growth.(112,169) Nevertheless, the
inductive cooperative potential of the transcription factors in cancer development and
progression seems to be even greater than simply the sum of their individual effects.
In the current study a subgroup was selected where snai1,  twist sip1 and slug were all
co-expressed in tumor epithelium. However, the number of positive cases remained too
small to permit any reliable statistical analyses.
6.3 Clinical implications
The expressions of EMT-RTFs, especially sip1, seem to have significant prognostic value in
PSCC.  Immunohistochemical  staining  is  a  relatively  fast,  cheap  and  simple  process
highlighting the possibility that it could be potential prognostic marker also for clinical use.
Detecting sip1 expression in PSCC could help us to select those patients who would benefit
from more aggressive treatment modalities and to follow-up them more carefully for
recurrences and second primaries.
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    Furthermore, activation of EGF-receptors has been shown to induce EMT.(243,244) At
present, EGFR inhibitors are the only targetted therapy approved for the treatment of
HNSCC; this drug selectively acts agianst epithelial cells and thus tumor cells which have
gone through EMT are protected from this chemotherapeutic agent.(132,244) EMT also
promotes DNA repair and suppresses radiation-induced apoptosis. Thus, the inhibition of
the EMT process could make tumors more sensitive to both radiation and chemotherapy.
Moreover, the inhibition of EMT process might also restrict tumor invasion and
metastasizing. EMT and its transcription factors in addition to its epigenetic regulation as
well  as  the  role  of  numerous  miRs  which  can  influence  EMT  may  create  considerable
number  of  potential  targets  for  new  cancer  therapeutics  in  the  future  by  for  example
silencing oncogenes or forced-expression of tumor suppressor genes. One major challenge
will be to identify those agents that selectively target mesenchymal cells and/or impact the
EMT process reversing the cellular alteration back towards the epithelial phenotype.
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7 Summary and conclusions
The  prognosis  of  PSCC  has  remained  poor,  poorest  of  all  HNCs,  in  spite  of  advances  in
diagnostics and treatment. Prognosis is still based almost solely by TNM-classification and
histological grading. New biomarkers are needed to select the patients with aggressive
tumors and poor survival prospects in order to target the treatment and follow-up
resources more effectively. The EMT process and its transcription factors provide several
possibilities for assessing tumor behavior.
Based on the results the following conclusions could be drawn:
1. T-class and general condition of the patient were the most important prognostic
factors. Histological grade offered no prognostic value.
2. Endothelial nuclear expression of snai1 predicted lower DSS. Snai1 expression in
other cell nuclei or cytoplasm had no statistically significant effect on survival.
3. Twist expression alone displayed no correlation with survival. Simultaneously, lack
of  both  snai1  and  twist  expression  in  tumor  stromal  cell  nuclei  predicted  better  5-
years DSS.
4. Sip1 expression in tumor epithelial cell nuclei was an independent prognostic factor
in PSCC. Furthermore, stromal nuclear expression of sip1 predicted poorer DSS. The
expression of slug or zeb1 did not associate with survival.
5. Co-expression of snai1, twist and sip1 in tumor epithelial nuclei is an independent
prognostic  factor  for  poor  survival  in  PSCC.  The  absence  of  stromal  nuclear  co-
expression of the three transcription factors was also significantly associated with
better survival.
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Anna Jouppila-Mättö
Epithelial-mesenchymal 
Transition and Expression 
of Its Transcription Factors 
in Pharyngeal Squamous 
Cell Carcinoma
Epithelial-mesenchymal transition 
(EMT) is a complex cellular process 
which is activated in tumorigenesis 
and enables tumor cells to invade and 
metastasize. It is regulated by several 
transcription factors i.e. snai1, twist, 
sip1, slug and zeb1. In the present 
retrospective study we evaluated the 
expression of these transcription 
factors in pharyngeal squamous cell 
carcinoma. The expression of sip1 
in carcinoma cells and tumor stroma 
associated with advanced tumor stage 
and predicted poorer DSS. 
